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ABSTRACT 
Long non-coding RNAs (lncRNAs) are a novel class of transcripts that are pervasively 
transcribed in the genome. Several lines of evidence correlate dysregulation of different 
lncRNAs to human diseases including neurological and autoimmune disorders, but their 
expression has not been exhaustively investigated in MS so far. 
The main aim of this study was to identify a specific signature of cellular and neural-
derived exosomal lncRNA expression.  
Regarding lncRNA expression levels from Peripheral Blood Mononuclear Cells 
(PBMC), we studied a discovery cohort of MS patients who were compared against 
controls. Results were validated in a larger cohort and further replicated in an 
independent Belgian population. 
LncRNA PCR arrays from System Bioscience (SBI) containing 90 common lncRNAs 
were used to screen lncRNA expression levels in PBMC from 5 patients with Relapsing 
Remitting (RR)-MS, 5 with Primary Progressive (PP)-MS and 5 age-matched controls. 
Results were validated by real time PCR in a further independent Italian cohort 
consisting of 30 PBMC samples from MS patients and 30 controls. Best hits were 
replicated using droplet digital PCR in a Belgian cohort consisting of 24 MS patients 
and 23 controls. 
In particular, in the Italian validation cohort ANRIL, TUG1, XIST (p<0.0001) and 
SOX2OT (p<0.001) were strongly down-regulated in RR-MS versus controls, while 
GOMAFU, HULC (p<0.0001) and BACE-1AS (p<0.001) showed a robust down-
regulation both in RR and Progressive MS in comparison with controls. NRON and 
TUG1 downregulation in MS patients, compared with controls (p<0.05 and p<0.0001 
respectively), was confirmed in the Belgian population. 
In addition, a protocol for the extraction and characterisation of neural-derived 
exosomes has been developed in order to investigate exosomal lncRNA expression 
levels. Using two types of commercial arrays, the human RT2 lncFinder array 
(QIAGEN) and the human RT2 lncRNA inflammation response and autoimmunity 
array (QIAGEN), generalised deregulation in exosomal lncRNA was observed. 
Moreover, the expression pattern of these molecules was different in RR-MS and in 
PP-MS. 
Precisely, results from the human RT2 lncFinder array (QIAGEN) analysis led to the 
identification of 7 most significantly deregulated lncRNAs, precisely AIRN (5.30-fold 
increase over controls, p=0.04); FAS-AS1 (4.76-fold increase over controls, p=0.02); 
HOTAIR (4.47-fold increase over controls, p=0.03); NAMA (13.24-fold increase over 
controls, p=0.01); TRERNA1 (5.84-fold increase over controls, p=0.01) and HOXA-
AS2 (0.56-fold increase over controls, p=0.04).  
Six lncRNA were significantly deregulated in the RR-MS subgroup, precisely AIRN 
(10.77-fold increase over controls, p=0.04); DLX6-AS1 (46.95-fold increase over 
controls, p=0.01); FAS-AS1 (11.37-fold increase over controls, p=0.001); HOTAIR 
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(9.31-fold increase over controls; p=0.02); and TRERNA1 (6.61-fold increase over 
controls, p=0.003). 
In PP-MS only SOX-2OT showed a significant upregulation (8.95-fold increase over 
controls, p=0.02). 
When we used the array containing lncRNA linked with inflammation and 
autoimmunity, MZF-AS1 (0.47-fold decrease over controls, p=0.03), CEP83-AS1 
(0.15-fold decrease over controls, p=0.02), RP11-282O18.3 (0.27-fold decrease 
over controls, p=0.02), RP11-84C13.1 (0.28-fold decrease over controls, p=0.04), 
SNHG7 (0.064-fold decrease over controls, p=0.04) and TP73-AS1 (0.48-fold 
decrease over controls, p=0.04) were significantly downregulated in MS, regardless 
of the subtype, while RP11-38P22.2 (19.5-fold increase over controls, p=0.04) 
showed an upregulation. 
Considering the disease subgroups, RR-MS patients showed a significant 
downregulation in RP11-363G2.4 (0.07-fold decrease over controls, p=0.008) and in 
TP73-AS1 (0.76-fold decrease over controls, p=0.02), while RP11-38P22.2 levels 
were upregulated (22.32-fold increase over controls, p=0.04). We found a general 
downregulation in lncRNA expression analysed in PP-MS, in particular FGF14-IT1 
(0.08-fold decrease over controls, p=0.007) and RP11-282O18.3 (0.14-fold 
decrease over controls, p=0.04) were significantly altered. 
Some important forms of dysregulation were observed, considering the expression 
levels of lncRNAs known to be involved in brain function and in neurological and 
autoimmune disorders. The rationale of this study might then be used to set up a future 
study with the purpose of selecting potential biomarkers for disease aggressiveness 
and possible response to therapy. 
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RIASSUNTO 
I long non-coding RNA (lncRNA) rappresentano una nuova classe di trascritti, che 
vengono prodotti a partire dal genoma. Diverse evidenze mostrano una correlazione 
tra un’alterata espressione dei lncRNA e differenti malattie dell’uomo, tra cui i disturbi 
autoimmuni e neurologici. Tuttavia, il loro ruolo nella sclerosi multipla (MS) non è 
ancora stato delucidato. 
Lo scopo principale di questo studio è stato quello di identificare una specifico 
pattern di espressione dei lncRNA, derivanti da cellule e contenuti negli esosomi di 
origine neuronale. 
In primis abbiamo studiato i lncRNA espressi dalle cellule mononucleate del sangue 
periferico (PBMC) in una coorte esplorativa di pazienti con MS e li abbiamo 
confrontati con dei soggetti di controllo. I risultati sono poi stati validati in una coorte 
più numerosa e ulteriormente replicati in una popolazione belga indipendente. 
Grazie a piastre contenenti 90 sonde complementari ai più studiati LncRNA (System 
Bioscience (SBI) abbiamo condotto uno screening in RT-PCR dei livelli di 
espressione dei lncRNA espressi nelle PBMC provenienti da 5 pazienti con la forma 
recidivante-remittente (RR-MS), 5 con la forma primariamente progressiva (PP-MS) 
e 5 controlli paragonabili per età. I risultati sono stati quindi validati in un'ulteriore 
coorte indipendente italiana composta da PBMC isolate da 30 pazienti con MS e da 
30 controlli, usando sonde Taqman in RT-PCR. I risultati migliori sono stati 
successivamente replicati utilizzando la tecnica di droplet digital PCR (ddPCR), in 
una coorte belga composta da 24 pazienti con MS e 23 controlli. 
In particolare, nella coorte di validazione italiana, i livelli di espressione di ANRIL, 
TUG1, XIST (p <0,0001) e SOX2OT (p <0,001) sono risultati fortemente ridotti nel 
gruppo RR-MS rispetto ai controlli, mentre GOMAFU, HULC (p <0,0001) e BACE- 
1AS (p <0,001) hanno mostrato una robusta alterazione sia nel gruppo RR-MS che 
in quello dei PP-MS rispetto ai controlli. La riduzione dei livelli di espressione di 
NRON e TUG1 nei pazienti con MS rispetto ai controlli (p <0,05 e p <0,0001 
rispettivamente) è stata confermata nella popolazione belga. 
 
Parallelamente, abbiamo messo a punto un protocollo per l'estrazione e la 
caratterizzazione di esosomi derivanti da neuroni, con il fine di indagare i livelli di 
espressione dei lncRNA contenuti in queste vescicole. Utilizzando due tipi di array 
commerciali, l'array human RT2 lncFinder (QIAGEN) e lo human RT2 lncRNA 
Inflammation response and autoimmunity (QIAGEN), è stata osservata una de-
regolazione generalizzata nei livelli di espressione dei lncRNA esosomali. Inoltre, il 
pattern di espressione di queste molecole era diverso nei sottogruppi dei RR-MS e 
dei PP-MS. 
Precisamente, i risultati dell'analisi dell'array human RT2 lncFinder (QIAGEN) hanno 
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portato all'identificazione di 7 lncRNA più significativamente alterati: AIRN 
(aumentato di 5,30 volte rispetto ai controlli, p = 0,04); FAS-AS1 (aumentato di 4,76 
volte rispetto ai controlli, p = 0,02); HOTAIR (aumentato di 4.47 volte rispetto ai 
controlli, p = 0,03); NAMA (aumentato di 13.24 volte rispetto ai controlli, p = 0,01); 
TRERNA1 (aumentato di 5,84 volte rispetto ai controlli, p = 0,01) e HOXA-AS2 
(aumentato di 0.56 volte rispetto ai controlli, p = 0,04). 
Sei lncRNA sono stati trovati significativamente alterati nel sottogruppo RR-MS: 
AIRN (aumentato di 10.77 volte rispetto ai controlli, p = 0,04); DLX6-AS1 (aumentato 
di 46.95 volte rispetto ai controlli, p = 0,01); FAS-AS1 (aumentato di 11.37 volte 
rispetto ai controlli, p = 0,001); HOTAIR (aumentato di 9.31 volte rispetto ai controlli; 
p = 0,02); e TRERNA1 (aumentato di 6.61 volte rispetto ai controlli, p = 0,003). 
Nel gruppo dei PP-MS solo SOX-2OT ha mostrato una espressione maggiore 
significativa (aumentato di 8.95 volte rispetto ai controlli, p = 0,02). 
Utilizzando l'array human RT2 lncRNA Inflammation response and autoimmunity 
(QIAGEN), MZF-AS1 (ridotto di 0.47 volte rispetto ai controlli, p = 0,03), CEP83-AS1 
(ridotto di 0.15 volte rispetto ai controlli, p = 0,02), RP11-282O18,3 (0,27 ridotto di 
0.27 volte rispetto ai controlli, p = 0.02), RP11-84C13.1 (ridotto di 0.28 volte rispetto 
ai controlli, p = 0,04), SNHG7 (ridotto di 0.0064 volte rispetto ai controlli, p = 0,04) e 
TP73-AS1 (ridotto di 0.48 volte rispetto ai controlli p = 0,04) hanno mostrato livelli 
significativamente ridotti in MS, indipendentemente dal sottotipo di malattia, mentre 
RP11-38P22.2 (aumentato di 19.5 volte rispetto ai controlli, p = 0,04) ha mostrato 
livelli di espressione maggiori se confrontato con soggetti di controllo. 
Considerando i sottogruppi di malattia, i pazienti RR-MS hanno mostrato livelli di 
espressione ridotti in RP11-363G2.4 (ridotto di 0.07 volte rispetto ai controlli, p = 
0,008) e in TP73-AS1 (ridotto di 0.76 volte rispetto ai controlli, p = 0,02). I livelli di 
RP11-38P22.2 sono, invece, aumentati (aumentato di 22.32 volte rispetto ai 
controlli, p = 0,04). Inoltre, abbiamo trovato un generale de-regolazione 
nell'espressione dei lncRNA analizzati nel sottogruppo dei PP-MS, in particolare 
FGF14-IT1 (ridotto di 0.08 volte rispetto ai controlli, p = 0,007) e RP11-282O18.3 
(ridotto di 0.014 volte rispetto ai controlli, p = 0,04) erano significativamente alterati. 
Considerando i livelli di espressione dei lncRNA notoriamente coinvolti nei disturbi 
neurologici e autoimmuni, sono emerse alcune importanti de-regolazioni. La logica 
di questo studio potrebbe quindi essere utilizzata per crearne uno futuro, allo scopo 
di selezionare potenziali biomarcatori di progressione della malattia e forse indici per 
valutare la risposta alla terapia. 
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SYMBOL INDEX 
A2ML1-AS1: A2ML1 antisense RNA 1  
Ab: antibody 
ABCA11P: ATP-binding cassette, sub-family A (ABC1), member 11, 
pseudogene 
ACTB: actin, beta 
AIRN: antisense of IGF2R non-protein coding RNA 
APC: antigen presenting cells 
ATXN8OS: ATXN8 opposite strand (non-protein coding) 
B2M: beta-2-microglobulin 
BAFF: B-Cell Activating Factor 
BANCR: BRAF-activated non-protein coding RNA 
BBB: blood brain barrier 
BCYRN1: brain cytoplasmic RNA 1 
BDNF-AS: BDNF antisense RNA 
BMI: Body Mass Index 
BOK-AS1: BOK antisense RNA 1 
CCAT1: colon cancer-associated transcript 1 (non-protein coding) 
CCAT2: colon cancer-associated transcript 2 (non-protein coding) 
CDKN2B-AS1: CDKN2B antisense RNA 1 
CEP83-AS1: CEP83 antisense RNA 1 (head-to-head) 
CHI3L1: chitinase-3-like protein 1 
CIS-MS: clinically isolated syndrome 
CNS: central nervous system 
COX2: cyclooxygenase 2 
CROCCP2: ciliary rootlet coiled-coil, rootlet in pseudogene 2 
CSF: cerebrospinal fluid 
DANCR: KIAA0114 
DC: dendritic cells 
DHFR: dihydrofolate reductase 
DIO3OS: DIO3 opposite strand (non-protein coding) 
DISC2: disrupted in schizophrenia 2 (non-protein coding) 
DLEU2: deleted in lymphocytic leukaemia 2 (non-protein coding) 
DLX6-AS1: DLX6 antisense RNA 1 
EAE: experimental autoimmune encephalomyelitis 
EBV: Epstein Barr virus 
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EDSS: Expanded Disability Status Scale 
EGOT: eosinophil granule ontogeny transcript (non-protein coding) 
EMX2OS: EMX2 opposite strand (non-protein coding) 
EPB41L4A-AS1: non-protein coding RNA 219 
ER: endoplasmic reticulum 
ERICH1-AS1: ERICH1 antisense RNA 1 
eRNA: enhancer RNA  
ESCRT: endosomal sorting complexes required for transport 
FACS: fluorescence-activated cell sorting 
FALEC: long intergenic non-protein coding RNA 568 
FAS-AS1: FAS antisense RNA 1 
FENDRR: hypothetical LOC400550 
FGD5-AS1: FGD5 antisense RNA 1 
FGF14-IT1: hypothetical LOC283480 
FITC: fluorescein isothiocyanate 
FLC: free light chain 
FOXN3-AS2: PRO1768 
FTX: FTX transcript, XIST regulator (non-protein coding) 
GACAT1: gastric cancer-associated transcript 1 (non-protein coding)  
GAS5: growth arrest-specific 5 (non-protein coding) 
GAS5-AS1: GAS5 antisense RNA 1 
GDP: guanosine 5'-diphosphate 
GEF: GDP/GTP exchange factor 
GNAS-AS1: GNAS antisense RNA 1 
GRM5-AS1: GRM5 antisense RNA 1 
GTP: guanosine triphosphate 
GWAS: genome-wide association study 
H19: H19, imprinted maternally expressed transcript (non-protein coding) 
HAR1A: highly accelerated region 1A (non-protein coding) 
HAR1B: highly accelerated region 1B (non-protein coding) 
HCG11: HLA complex group 11 (non-protein coding) 
HCG18: HLA complex group 18 (non-protein coding) 
HEIH: hepatocellular carcinoma upregulated EZH2-associated long non-
coding RNA 
HIF-1: hypoxia-inducible factor 1 
HLA: human leukocyte antigen 
HNRNPU-AS1: HNRNPU antisense RNA 1 
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HOTAIR: HOX transcript antisense RNA (non-protein coding) 
HOTAIRM1: HOXA transcript antisense RNA, myeloid-specific 1 
HOTTIP: HOXA distal transcript antisense RNA 
HOXA11-AS1: HOXA11 antisense RNA 1 (non-protein coding) 
HOXA-AS2: HOXA cluster antisense RNA 2 
HOXA-AS3: HOXA cluster antisense RNA 3 
HTR4-IT1: HTR4 intronic transcript 1 (non-protein coding)  
HULC: hepatocellular carcinoma upregulated long non-coding RNA 
IEF: isoelectric focusing 
IFN: interferon 
Ig: immunoglobulin 
IGF2-AS: insulin-like growth factor 2 antisense 
IL: interleukin 
ILV: intraluminal vesicles 
IMSGC: International Multiple Sclerosis Genetics Consortium 
iPSc: induced pluripotent stem cells 
IPW: imprinted in Prader-Willi syndrome (non-protein coding) 
IQCF5-AS1: IQCF5 antisense RNA 1 
JPX: JPX transcript, XIST activator (non-protein coding) 
KCNIP4-IT1: KCNIP4 intronic transcript 1 (non-protein coding) 
KCNQ1OT1: KCNQ1 overlapping transcript 1 (non-protein coding) 
KIR: killer-cell immunoglobulin-like receptor 
KRASP1: Kirsten rat sarcoma viral oncogene homolog pseudogene 1  
L1CAM: L1 cell adhesion molecule 
LINC00094: long intergenic non-protein coding RNA 94 
LINC00116: long intergenic non-protein coding RNA 116 
LINC00293: long intergenic non-protein coding RNA 293 
LINC00324: long intergenic non-protein coding RNA 324 
LINC00421: HCG2019585-like 
LINC00570: long intergenic non-protein coding RNA 570 
LINC00581: long intergenic non-protein coding RNA 581 
LINC00599: hypothetical LOC157627 
LINC00635: hypothetical LOC151658 
LINC00657: long intergenic non-protein coding RNA 657 
LINC00662: long intergenic non-protein coding RNA 662 
LINC00667: hypothetical LOC339290 
LINC00853: long intergenic non-protein coding RNA 853 
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LINC-ROR: long intergenic non-protein coding RNA, regulator of 
reprogramming 
lncRNA: long non coding RNA 
LOC100287846: patched 1 pseudogene 
LOC101927156: uncharacterised LOC101927156 
LOC653160: uncharacterised LOC653160 
LRRC37BP1: leucine rich repeat containing 37B pseudogene 1 
LRRC75A-AS1: Non-protein coding RNA 188 
LUCAT1: lung cancer-associated transcript 1 (non-protein coding) 
MAG: myelin-associated glycoprotein 
MALAT1: metastasis-associated lung adenocarcinoma transcript 1 (non-
protein coding) 
MBP: myelin basic protein 
MCM3AP-AS1: MCM3AP antisense RNA 1 (non-protein coding) 
MEG3: maternally expressed 3 (non-protein coding) 
MEG9: maternally expressed 9 (non-protein coding) 
MHC: major histocompatibility complex 
MIAT: myocardial infarction-associated transcript (non-protein coding) 
miRNA: micro RNA 
MOG: myelin oligodendrocyte glycoprotein 
MRI: magnetic resonance imaging 
MRPL23-AS1: MRPL23 antisense RNA 1 
MS: multiple sclerosis 
MSGB: multiple sclerosis genetic burden 
MVB: multivesicular bodies 
MZF1-AS1: uncharacterised LOC100131691 
NAA: n-acetylaspartate 
NAMA: non-protein coding RNA, associated with MAP kinase pathway and 
growth arrest 
NAV2-AS5: NAV2 antisense RNA 5 
NCBP2-AS2: hypothetical LOC152217 
NEAT1: nuclear paraspeckle assembly transcript 1 (non-protein coding) 
NFAT: nuclear factor of activated T-cells 
NfH: neurofilament high protein 
NF-kB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NfL: neurofilament light protein 
NMO: neuromyelitis optica 
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NRON: non-protein coding RNA, repressor of NFAT 
NUTM2A-AS1: NUTM2A antisense RNA 1 
OCB: oligoclonal bands 
OIP5-AS1: OIP5 antisense RNA 1 
OTX2-AS1: OTX2 antisense RNA 1 (head-to-head) 
PANDAR: promoter of CDKN1A antisense DNA damage activated RNA 
PBMC: peripheral blood mononuclear cell 
PBS: phosphate-buffered saline buffer 
PCAT1: prostate cancer-associated transcript 1 (non-protein coding) 
PCGEM1: prostate-specific transcript 1 (non-protein coding) 
PCR: polymerase chain reaction 
PDXDC2P: pyridoxal-dependent decarboxylase domain containing 2, 
pseudogene 
PLP: proteolipid protein 
PP-MS: primary progressive form 
PRC: polycomb repressor complex 
PRINS: psoriasis-associated non-protein coding RNA induced by stress 
PSMA3-AS1: hypothetical LOC379025 
PTCSC1: papillary thyroid carcinoma susceptibility candidate 1 (non-protein 
coding) 
PTCSC3: papillary thyroid carcinoma susceptibility candidate 3 (non-protein 
coding) 
PTENP1: phosphatase and tensin homolog pseudogene 1 
PTENP1-AS: PTENP1 antisense RNA 
RBM5-AS1: RBM5 antisense RNA 1 
RISC: RNA-induced silencing complex 
RMST: rhabdomyosarcoma 2-associated transcript (non-protein coding) 
RN7SK: RNA, 7SK small nuclear 
RNApol-II: RNA polymerase II 
RNP: ribonucleoprotein complexes 
RNS: reactive nitrogen species 
ROS: reactive oxygen species 
RP11-399K21.11: uncharacterized LOC101929189 
RPLP0: ribosomal protein, large, P0 
RPS6KA2-AS1: RPS6KA2 antisense RNA 1  
RQ: relative quantity 
RR-MS: relapsing remitting form 
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RT-PCR: real time polymerase chain reaction 
SD: Standard deviation 
SDCBP2-AS1: SDCBP2 antisense RNA 1 
SENP3-EIF4A1: SENP3-EIF4A1 readthrough (NMD candidate) 
SIK3-IT1: SIK3 intronic transcript 1 (non-protein coding) 
SIX3-AS1: SIX3 antisense RNA 1 
SLC7A11-AS1: SLC7A11 antisense RNA 1 
SNAP: NSF-attachment protein   
SNARE: SNAP-attachment protein receptor 
SNHG11: small nucleolar RNA host gene 11 (non-protein coding) 
SNHG16: small nucleolar RNA host gene 16 (non-protein coding) 
SNHG20: long intergenic non-protein coding RNA 338 
SNHG5: small nucleolar RNA host gene 5 (non-protein coding) 
SNHG7: small nucleolar RNA host gene 7 (non-protein coding) 
SNORA73A: small nucleolar RNA, H/ACA box 73A 
SNP: single nucleotide polymorphism 
SOX2-OT: SOX2 overlapping transcript (non-protein coding) 
SP-MS: secondary progressive form 
SPRY4-IT1: SPRY4 intronic transcript 1 (non-protein coding) 
ST7-AS1: ST7 antisense RNA 1 
ST7-AS2: ST7 antisense RNA 2 
TEM: transmission electron microscope 
TERC: telomerase RNA component 
TERRA: lncRNA-associated with telomeres 
TF: transcription factors 
TINCR: placenta-specific 2 (non-protein coding) 
TLR: toll-like receptor 
TMEM161B-AS1: TMEM161B antisense RNA 1 
TP73-AS1: TP73 antisense RNA 1 (non-protein coding) 
TRERNA1: translation regulatory long non-coding RNA 1 
TSIX: TSIX transcript, XIST antisense RNA (non-protein coding) 
T-UCR: ultra-conserved transcripted regions  
TUG1: taurine upregulated 1 (non-protein coding) 
TUNAR: TCL1 upstream neural differentiation-associated RNA 
TUSC7: tumor suppressor candidate 7 (non-protein coding) 
UCA1: urothelial cancer-associated 1 (non-protein coding) 
UVR: ultraviolet radiation 
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VEGF: vascular endothelial growth factor 
WT1-AS: WT1 antisense RNA (non-protein coding) 
XIST: X (inactive)-specific transcript (non-protein coding) 
ZFAS1: ZNFX1 antisense RNA 1 
ZNRD1-AS1: ZNRD1 antisense RNA 1 (non-protein coding) 
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1. INTRODUCTION 
1.1 Multiple Sclerosis 
Multiple Sclerosis (MS) is the most common progressive disease of the 
central nervous system in young adults and the most common cause of 
serious physical disability in adults of working age [1].  
MS is pathologically characterised by focal areas of inflammation, 
demyelination, gliosis, and axonal damage throughout the central nervous 
system (CNS). MS disease presentation is very heterogeneous with variable 
clinical manifestations that evolve over time. About 80% of patients present 
with relapsing-remitting disease (RR-MS). This form of the disease is 
characterised by relapses followed by periods of partial or complete recovery 
(remissions). Other subtypes of MS include primary progressive MS (PP-
MS), which shows progressively worsening disability from the onset, and 
secondary progressive MS (SP-MS), in which patients develop RR-MS but 
then begin progressing with or without relapses [2,3]. 
 
Physicians have described possible MS cases since the Middle Ages. 
Lidwina of Schiedam is probably the first documented case, and dates back 
to 1421. Her biographers claim that she suffered episodes of paralysis since 
she was 16, and that she became progressively worse, until her death. She 
even became blind. We have to wait for five centuries to read about a new 
MS case, when Augusto Federico d’Este decided to describe the progress 
of his disease in a diary.  
When doctors began to scientifically analyse illnesses, MS was among the 
first diseases to be studied. Drawings from autopsies performed as early as 
1838 clearly show what we now recognise as MS. Then, in 1868, Jean-Martin 
Charcot carefully examined a young woman with a tremor of a sort he had 
never seen before. He noticed her other neurological problems, including 
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slurred speech and abnormal eye movements, and compared them to other 
patients he had seen. When she died, he examined her brain and found the 
characteristic scars or “plaques” of MS. Dr. Charcot wrote a complete 
description of the disease and the changes in the brain that accompany it. 
However, he was baffled by its cause and frustrated by its resistance to all 
his treatments. The three signs of MS, nystagmus, intention tremor, and 
telegraphic speech were called Charcot’s triad. Charcot also observed 
cognitive changes, describing his patients as having a "marked 
enfeeblement of the memory" and "conceptions that formed slowly".  
 
Scientists began to understand the pathogenesis and progression of the 
disease more in detail in the 20th century, when sophisticated techniques 
improved research tools [4]. Since the description of MS by Charcot in the 
nineteenth century, there has been an increasingly important need to 
accurately diagnose MS. Today the current diagnostic criteria for MS are 
McDonald’s criteria, published in 2001 by a team led by Prof. Ian McDonald, 
and revised in 2005 and 2010 [5,6].  
Despite the remarkable progress made by research on the mechanisms of 
MS, today there is no cure for multiple sclerosis. Treatment typically focuses 
on speeding up recovery from attacks, slowing down progression of the 
disease and managing MS symptoms.  
MS is one of the most socially expensive disease. The costs of the disease 
are ascribable to age of onset, duration of the disease and welfare costs; 
indeed it hurts the most productive class of the population. As Owens said in 
his report “in 2012 the average costs for all privately insured patients with MS 
were $30,000 annually” [7]. 
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1.1.1 Epidemiology 
 
2.5 million people worldwide have MS, in particular 630,000 in Europe and 
58,000 in Italy [8].  
Typically, the onset of the disease ranges from 20 to 45 years, with an 
incidence peak of 25-30 years, although cases of childhood or late onset are 
reported. MS with childhood onset is a rare condition (<5% of all MS cases) 
[9].  
The overall incidence rate of MS was 3.6 cases per 100,000 person-years 
(95% CI 3.0, 4.2) in women and 2.0 (95% CI 1.5, 2.4) in men [9]. Recently 
the gender ratio has become higher than in the past, and is indirectly a 
marker of an increased incidence of MS in women. This might reflect the 
changes in lifestyle, i.e., smoking, attitude, stress, obesity, use of oral 
contraceptives, later pregnancy, that could play an important role in MS 
aetiology [1]. Another reason for this gender prevalence might be found in 
the dimorphism between the two sexes, associated with genetic and 
hormonal factors, as well as in the intrinsic biological differences of the 
immune and nervous system [10]. 
MS is more common in high income countries, and it presents a 
heterogeneous prevalence in the world; precisely, in Europe and North 
America we find the highest incidence with 108 cases/100,000 and 140 
cases/100,000, respectively, while the lowest incidence is in Sub-Saharan 
Africa and in East Asia (~2.0 cases/100,000) [1] [Figure 1].  
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Figure 1. Global prevalence of MS in 2013 [11] 
 
In 1975, some evidence led Kurtzke to define three different zones of global 
prevalence rating: high (30–80/100,000), medium (5–25/100,000) and low 
zones (<5/100,000). Northern United States, Canada, New Zealand, 
Australia, most of Northern Europe and Israel generally belong to the first 
group. Southern Europe, southern United States and northern Australia are 
the medium zones, while Asia, South America and most of Africa are 
included in the low zones [12]. Hence the concept of the “geographical 
gradient north-south”. According to this idea, some genetic and 
environmental factors have a gradient frequency that corresponds to a 
latitude variation. In particular, environment, infections, smoking, exposure 
to sunlight and vitamin D levels were associated with MS risk. Regarding 
genetics, it was noticed that in high risk areas, some racial groups maintain 
a low prevalence of disease (Japanese and other Asians living in Great 
Britain, African Americans, Africans in South Africa). In addition, recent 
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studies have shown the correlation between the risk of MS and the place 
where childhood years were spent, and have underscored the impact of 
migrations [8]. 
Despite this evidence, the “gradient concept” has been currently questioned, 
since several exceptions have emerged [1]. For example, the idea that Italy 
represents a medium risk area, compared to Northern Europe, has been 
reviewed by epidemiological studies conducted over recent years, which 
have shown a prevalence of 30 to 70 cases/100,000 inhabitants, placing Italy 
among high risk countries [3,13]. Moreover, in our country the disease 
presents no reduction as the latitude diminishes from North to South. Indeed, 
MS has a high incidence in Sicily and Sardinia probably because of the 
founder effect and different genetic ancestry (in particular for Sardinia). 
Given the above, further population studies are required also because the 
knowledge of epidemiology and natural history of MS might help to highlight 
the pathogenesis of the disease and lead to an effective therapy. As Simpson 
et al. wrote: “While classic epidemiological methods are ongoing, novel 
avenues for research include gene-environment interaction studies, the 
world of ‘-omic’ research, and the utilization of mobile and social media tools 
to both access and track study populations, which means that the 
epidemiological discoveries of the past century may be but a glimpse of our 
understanding in the next few decades” [14]. 
1.1.2 Aetiology and pathogenesis of MS 
Strong evidence underpins the fact that MS is a disease caused by different 
factors. Not only genetics, but also lifestyle and environmental factors 
predispose an individual to develop clinical MS and might act in the 
subclinical phase, before the onset. 
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Genetic factors 
Epidemiological analyses have revealed that MS cluster in families, 
determined by genetic factors. The familial recurrence rate is about 20% and 
the reduction in risk changes from 3% to 1%, if we consider first degree 
relatives, in comparison with second and third degree relatives [2] [Figure 2]. 
 
Figure 2. Risk of MS recurrence in families [2]  
 
Analysing families with MS, it is rare to find more than 3 or 4 cases, and 
extended families with many affected subjects are uncommon [15].   
  
Over the past 10 years, an international collaborative project organised by 
the International Multiple Sclerosis Genetics Consortium (IMSGC) – 
identified >100 genetic risk factors for MS. Ongoing projects increase this 
number to approximately 200 common risk variants and are expected to 
reach the limit of common genetic risk variants that are realistically 
detectable at this time. It was demonstrated that these variants have 
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enriched immunological function, and overlap with other autoimmune but not 
neurological disorders [16]. 
Genetic susceptibility to the disease is probably multifactorial, linked to many 
genes, and does not follow a Mendelian inheritance. Since the 1970s, the 
association has been known between MS and genes encoding leucocyte 
antigen (HLA) contained within the MHC, but it is difficult to identify the 
variant that drives these correlations. Indeed, this gene region is 
characterised by extreme polymorphism and extensive linkage 
disequilibrium.  
In particular, HLA class II 
and I genes are the most 
relevant as modifier of MS 
risk [Table 1]. The HLA-
DRB1*15:01 lead to the 
haplotype that is mainly 
associated with the 
development of the disease. 
Instead, it has been 
confirmed that the HLA-
A*02:01 allele has a protective 
effect [17]. 
 
Moutsianas et al. 2015 not only confirmed the important role of HLA class II 
risk alleles (HLA-DRB1*15:01, HLA-DRB1*13:03, HLA-DRB1*03:01, HLA-
DRB1*08:01 and HLA-DQB1*03:02) and of class I protective alleles (HLA-
A*02:01,HLA-B*44:02, HLA-B*38:01 and HLA-B*55:01) in MS aetiology, but 
also described interactions involving pairs of class II alleles, such as HLA-
DQA1*01:01–HLA-DRB1*15:01 and HLA-DQB1*03:01–HLA-DQB1*03:02 
[18]. 
Table 1. Multiple sclerosis risk alleles in MHC 
[19]  
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As mentioned, genome-wide association studies (GWAS) have identified 
~100 non-HLA single nucleotide polymorphisms (SNPs) that are mildly 
associated with MS susceptibility. Independent evidence has underscored 
how SNP rs6897932 from the IL7R gene plays an important role in the 
disease risk, and new variants in specific genes involved in MS inflammatory 
pathways were later identified. In most cases, the role of these genes is to 
regulate lymphocyte function, particularly in the activation and proliferation 
phase of the T-cell population. They can also be involved in the cytokine 
cascade, such as CXCR5, IL2RA, IL7R, IL7, IL12RB1, IL22RA2, IL12A, 
IL12B, IRF8, TNFRSF1A, TNFRSF14, and TNFSF14. They can act as 
regulatory molecules, such as CD37, CD40, CD58, CD80, CD86, CLECL1, 
and receptor molecules implicated in signal transduction processes [17,19]. 
Recent studies have attributed a role in MS aetiology to the mutation with 
loss of function of the enzyme CYP27B1, which is responsible for the 
conversion of 25-hydroxyvitamin D into 1,25-dihydroxyvitamin D. This 
confirms the role of vitamin D in determining the disease [20]. 
 
The association between KIR (killer-immunoglobulin-like receptors) and MS 
have recently been studied. They are highly polymorphic receptors 
expressed by natural killer cells and regulate cell killing and the cytokine 
response. Since many HLA class I molecules act as ligands for KIR, probably 
some associations observed between KIR and MS susceptibility actually 
result from their function. They can also be expressed by CD4+ and their 
alterations may affect the production of specific antibodies, explaining their 
role in the pathogenesis of MS. In particular, MS susceptibility increases if 
KIR are absent, while the presence of different types of KIR may be a 
24 
 
protective factor. Hence the possible role of NKs as players in the 
pathogenesis of MS [21]. 
 
Since the majority of associations related to variants are common in the 
general population, we can talk about the presence of “cumulative genetic 
risk” in MS, defined by MS genetic burden (MSGB). Gourraud et al. 2012 
defined the MSGB as ”a score based on an algorithm that incorporates each 
risk variant for a given individual and weighs each SNP according to its 
reported effect size. The MSGB score quantitatively represents the known 
MS genetic risk for each individual.” The MSGB score gives an opportunity 
to analyse cases in the context of whole populations as well as the possibility 
of personalised care [22]. 
 
Epigenetic factors 
Extensive data on the involvement of epigenetic mechanisms in the onset of 
MS have been collected in the past few years. Elements supporting this 
hypothesis include the probable maternal transmission of the disease, 
environmental risk factors, such as Vitamin D deficiency, smoking and 
Epstein Barr virus, which can induce epigenetic modifications.  
Regarding MS, twin studies revealed epigenetic differences, particularly in 
the DNA methylation and acetylation pattern and in the female predominant. 
This gender influence suggests a possible epigenetic effect on specific genes 
located in the X chromosome. Moreover, the mother transmits HLA-DRB1*15 
allele more than father, underling a parent-of origin effect [23].  
Some evidence showed alterations in the promoter methylation status of 
genes, in PBMC and/or brain samples, though histone acetylation seems to 
be the most crucial event in MS aetiology. Moreover some data described an 
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increase or decrease in acetylation, methylation and citrullation of genes 
involved in the inflammatory response and demyelination process [24,25]. At 
the post-transcriptional level, micro-RNA (miRNA) control epigenetics 
through the RNA-induced silencing complex (RISC) and long non-coding 
RNA (lncRNA). miRNA-RISC modulate cellular pathways, such as 
apoptosis, proliferation and differentiation [26], while lncRNA regulate gene 
expression at the epigenetic, transcriptional, and post-transcriptional level in 
cellular homeostasis [27] . Table 2 summarises the major epigenetic 
mechanisms involved in the pathogenesis of MS.  
 
Table 2. Epigenetic mechanisms in MS [24] 
 
As Fenoglio et al. 2012, wrote: “Preliminary studies have started to analyze 
the possible genetic contribution of miRNA loci variability in MS, suggesting 
that the research on miRNAs has finally begun to be approached in a more 
comprehensive and definitive manner.” [28] 
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In recent years, researchers have found a large number of dysregulated 
miRNAs in serum, plasma and PBMC from MS patients, as well as in brain 
lesions. At times the miRNA profile showed similarities in both active lesions 
and in blood, such as the upregulation of miR-326, but the alteration can also 
be different sometimes. This happens for miR-323, which showed an 
upregulation in whole blood, active brain lesions, and T-reg cells, but not in 
the serum of MS patients [29]. 
Interestingly, growing evidence demonstrates that also lncRNAs get dragged 
into different cell pathways as, for example, in the regulation of immune cell 
activity. Regarding this issue, Spurlock et al. identified specific expression 
patterns in lymphocyte lineages [30]. Since it is a known fact that these cells 
are involved in the pathogenesis of MS, lncRNAs may control important steps 
of their imbalanced activity [31,32], suggesting that they could be associated 
with progression of the disease. 
Environmental factors 
Next to genetic factors, environment and lifestyle can influence the 
pathogenic pathways of MS and lead to the clinical disease. These factors 
affect the immune system to trigger and/or perpetuate the disease.  [Figure 
3] 
The importance of environmental factors is demonstrated not only by the 
epidemiological characteristics of the geographical distribution of MS, but 
also by monozygotic twin studies. These indicate, with a concordance 
frequency of about 30%, that the aetiology of the disease cannot be 
explained only considering genetics.  
In addition, several epidemiological migration studies have shown that 
populations tend to maintain the risk of developing MS in the area of origin 
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when migration occurs after the 15th year of life, while on the other hand they 
acquire the risk of the new country of residence when migration occurs 
before the 15th year of life [33,34]. These data suggest, therefore, the 
presence of environmental factors that affect the subject during childhood or 
early adolescence. 
 
 
Figure 3. Environmental factors and the immune system [35] 
 
Hence, the period of exposure to certain factors is also significant. Recent 
migration studies also confirm the evidence of a risk attributable to 
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environmental factors, without  recognising a precise cut-off age for their 
influence [33]. 
Other non-genetic risk factors include smoking, Epstein-Barr virus (EBV) 
infections, vitamin D levels and sun exposure, obesity during adolescence 
and diet [Table 1] [36,37].  
 
Table 3. Environmental risk factors for MS [35] 
 
There is a positive correlation between smoking or passive exposure and the 
increased risk of MS. Interestingly, some studies underlined that smoking is 
also associated with the development of neutralising antibodies against 
some MS therapies, such as Natalizumab and IFN-β [38,39]. The 
hypothetical mechanism of action of smoking is described in [Figure 4]. 
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Smoking promotes the activation of inflammation in the lungs, and leads to 
an altered post-translational event of inflammatory molecules. These events 
cause activation of resident CD4+ CNS-antigen-specific T cells through HLA-
DRB1*15:01 proteins. This hypothesis is supported by some experiments in 
experimental autoimmune encephalomyelitis (EAE), an MS animal model 
[37].    
 
Figure 4. Mechanisms of smoking-associated processes in MS [35]. 
  
The hypothesis according to which some bacterial or viral agent can be the 
cause of MS is particularly important. Currently, it is unclear whether it is a 
general infection or a specific agent that can trigger the disease or whether 
tissue damage is a direct or indirect effect of the infection. Anyway, some 
infective agents were isolated from MS patient serum and CSF, and some of 
them were also found in demyelinating plaques: Chlamydia pneumonie, 
Mycoplasma pneumonie, EBV, HHV-6, Coronavirus [40]. Among these, 
some evidence suggests that the most interesting candidate is EBV. Indeed, 
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MS patients have higher levels of EBV nuclear antigen1 antibodies (EBNA1), 
and Handel et al. 2010 demonstrated that people who had EBV infection 
have an >2-fold increased risk of MS [41]. Furthermore, there are some 
interactions between HLA DRB*15:01 and the mononucleosis agent [42]. 
Overall, these observations confirm a bond between EBV and MS, although 
its role needs to be clarified.  
In recent years, several studies have focused on microbiota and found that 
different strains of bacteria differ in terms of capability to cause 
neuroinflammation. Hence the hypothesis that the type and distribution of gut 
bacteria could be considered as a risk factor for MS [37]. 
Epidemiological studies determined ultraviolet radiation (UVR) and vitamin D 
as protective factors against the onset of MS. This is linked with a latitude-
dependent variation in the incidence and prevalence of MS. On the one hand 
sun exposure reduces peripheral inflammation, and on the other hand high 
levels of vitamin D, especially in adolescence, are protective against axonal 
injury. Though the physiological mechanism has not been understood, 
people presenting MS with high levels of vitamin D have a reduction in axonal 
damage and low levels of neurofilaments in biological fluids [43]. Therefore, 
considered together, these factors are able to mitigate a future MS risk. 
Growing evidence underpins the fact that obesity, in particular during 
adolescence, can play a role in the pathogenesis of MS. Indeed, 
adolescence seems to be the crucial period in which weight affects the 
develop of MS. Munger underscored a strong correlation between Body 
Mass Index (BMI) > 27 [44], and Hedstrom 2014 too described an interaction 
between BMI-HLA variants [45]. Inflammatory processes are involved, since 
obesity promotes the production of cytokines and leptin, with a reduction in 
Treg cells and vitamin D bioavailability. All of these events might enhance the 
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activation of adaptive autoreactive immune cells and can trigger 
neuroinflammatory activity [37].  
 
Pathogenesis of multiple sclerosis 
The exact cause of multiple sclerosis is still unknown, but to date it is clear 
that different factors contribute to the onset of disease processes, such as 
neuroinflammation, demyelination, gliosis and neurodegeneration.  
Without a main risk factor, we do not know if multiple sclerosis is triggered in 
CNS or in peripheral regions of the body. In the most acclaimed model, a 
peptide molecule from a foreign antigen closely resembling part of a self-
protein is presented to T cells (molecular mimicry event) [46], or to antigen-
presenting cells (APC) (bystander activation) [47] that are consequently 
activated, and trigger an autoimmune reaction. Therefore, in case of reduced 
regulatory T (Treg) function and/or if lymphocytes B and T show resistance to 
suppressive mechanisms, CNS-directed autoreactive B and T cells can be 
activated. The inflammation processes start with the differentiation of CD8+ 
T cells into CD4+ T helper cells (TH1and TH17 cells) and with the following T, 
B and immune cell infiltration into the CNS. Exposure to specific 
environmental factors or genetic predisposition contribute to these events 
[Figure 5] [48]. 
As mentioned, autoreactive T cells escape central tolerance in the thymus. 
In healthy subjects, T cells with high affinity for self-antigen are led to 
apoptosis by peripheral tolerance processes. However, autoreactive 
lymphocytes may be released in peripheral regions due to a stochastic 
phenomenon. Indeed, the thymus might produce a limited number of APCs, 
or these cells might have a reduced capability to interact and induce T cell 
32 
 
apoptosis. Consistently with this theory, some studies demonstrated that 
these autoreactive cells overexpress β-arrestin 1,  a key promoter of naïve 
activated CD4+ T cell survival [49]. In addition, the presence of specific 
variants in HLA genes, linked with MS susceptibility, could help to break the 
tolerance. 
 
Figure 5. Immune system dysregulation outside the CNS [48] 
 
In MS, T cells are autoreactive against the myelin component, in particular 
myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) , 
myelin associated glycoprotein (MAG) and proteolipid protein (PLP) [50]. 
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Although these are the main protein candidates, other antigens seem to be 
implicated in the early disease processes. For instance, αB crystalline protein 
is described as preventing suppression of the inflammation [51], and 
neurofascin as mediator of axonal injury [52].  During the initial stage of the 
disease, the immune response is mainly focused on an immuno-dominant 
epitope and clonal lymphocytic populations mediate it. Subsequently, a 
phenomenon known as epitope spreading occurs with an increasing number 
of antigen molecules resulting from initial tissue damage being exposed to 
the extracellular environment, and becoming the target of the autoimmune 
response [53].  
As a secondary phenomenon, there is the infiltration of autoreactive 
lymphocytes into the CNS. T cells migrate across the blood-brain barrier 
(BBB) and the CSF-barrier. Though the CNS is an immune-privileged site, 
its isolation is not absolute. Indeed, blood-derived innate immune cells might 
stay in ventricular, meningeal and perivascular spaces in order to activate 
CNS-resident T cells when there is an important inflammatory condition [54]. 
Perivascular astrocytes might contribute to change BBB permeability, 
producing  VEGF and HIF-1 after inflammatory signal stimulation [55]. Since 
local regulatory processes fail in MS, T cells infiltrate and become localised 
in different regions, such as cortex and subcortical white matter, in the optic 
nerve and brainstem, or cluster around the corpus callosum and lateral 
ventricles. Here they form the so-called inflammation plaques, which are 
visible by MRI [8].  
Lymphocyte migration through brain endothelium is a multi-step process, 
which involves a complex interaction between adhesion molecules (such as 
selectins and integrins), chemokines and proteases. In physiological 
conditions, chemokines are confined to the parenchymal side. After a 
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stimulus, they are exposed to vessels in order to facilitate lymphocytic 
extravasation. CCL19, CCL21 and CXCL12 seem to be mainly involved in 
MS pathogenesis [56]. After extravasation, T-lymphocytes have to cross the 
extracellular matrix, which is made up of type IV collagen. Here the 
metalloproteases (gelatinases A and B, collagenase) play a key role in 
helping T cells to penetrate into the white substance of the CNS.  
In the CNS, infiltrated CD4+ T cells are re-activated by APC and recruit 
monocytes and naïve CD4+ T. Thus activated, these preferentially 
differentiate into TH1 and TH17 cells, secreting INFγ and cytokines, such as 
IL-17A. Following antigen recognition, the activated T CD4+ and CD8+ 
lymphocytes release cytokines (IL-1, TNF-α, IL-12, IL-17) and chemokines 
(IP-10, RANTES, MIP-1a). Moreover, they induce apoptotic signals and 
activation of other lymphocytic populations. Compared with T cells, B cells 
are also involved in disease progression, destroying myelin and fuelling of 
the inflammation fire.  
Given the above, chronic inflammation is thus established [Figure 6]. 
Focal inflammatory response in the CNS results in destruction of myelin, 
oligodendrocyte death and Wallerian degeneration of the axons. This 
evolution of late plaque is the result of ineffective re-myelination by 
oligodendrocyte precursors, probably due to continuous inflammatory insult 
in the course of time. According to some evidence, the loss of 
oligodendrocytes might be due, at least partly, to apoptosis without mediation 
of immunity [57]. It has, therefore been hypothesised that the immune system 
acts as a trigger for a neurodegenerative process that can become 
spontaneous in time. 
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Key neurodegenerative processes in MS are the consequences of chronic 
inflammation. Indeed, they are associated with the production of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS). These 
phenomena cause mitochondrial injury and subsequent ER stress and 
energy deficiency. Since normal neuroaxonal functions require a lot of 
energy, in pathological conditions we have the loss of neuronal health with 
critical implications for the neuron. Therefore, neurodegeneration and 
demyelination seem to be mediated at least by oxidative damage, correlated 
with age. It remains to be established whether the initial damage is due to 
the release of pro-inflammatory cytokines by the cells involved in chronic 
inflammation, with the establishment of a specific pattern of microglia 
activation and the initiation of oxidative cascade or, alternatively, whether it 
is triggered by a hypothesised soluble demyelinating factor that is 
responsible for the initial damage, which is then maintained [58]. 
Moreover, in order to maintain ion homeostasis, different ion channels 
change their distribution following demyelination [Figure 7]. A series of 
buffering mechanisms are triggered to cope with this situation, but they do 
not suffice to guarantee neuron survival [57]. 
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Figure 6. Immune system dysregulation in the CNS [48] 
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Figure 7. Key neurodegenerative processes [48] 
Although neurodegeneration processes are the culmination of a cascade of 
inflammatory events implemented by infiltrated immune cells, they can also 
be sustained by cells that are already resident in the CNS. Indeed, infiltrated 
cells also activate CNS-resident microglia and astrocytes, and through 
soluble inflammatory and neurotoxic molecules they promote 
oligodendrocyte and neuron injury, as well as demyelinating events. In 
particular, astrocytes produce CCL2 and GM-CSF in response to stimulated 
microglia, and this leads to even further microglial recruitment. 
Physiologically, microglia have a neuroprotective capacity by helping to 
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resolve inflammation. They produce neurotrophic factors, maintain CNS 
homeostasis and are involved in neuroaxonal injury repair. In pathological 
conditions, microglia change phenotypes and their functions, and might 
promote tissue damage, sustaining inflammatory processes [48].  
The described processes involved in MS pathogenesis are complex and, 
sometimes, difficult to fully understand. Though we have consistently 
answered many questions regarding the development of MS, important 
points remain to be finally clarifies in order to find an effective therapy. 
1.1.3 Pathophysiology 
 
Myelin is a fatty white substance that winds concentrically around the neural 
axon. Myelin function consists in isolating the nervous impulse that rapidly 
propagates from the cellular body along the axon, passing from one Ranvier 
node to the next with a saltatory conduction mode.  
The main physiological effect resulting from demyelination is the prevention 
of efficient electrical conduction, with a reduction in action potential velocity. 
Depolarisation might cross the lesion but with reduced velocity, which is a 
feature of evoked potentials. This slow nerve conduction in the pyramidal 
path is probably responsible for the sense of fatigue [2]. Instead, the 
significant increase in sensitivity in demyelinated nerve fibres explains the 
rapid onset of certain clinical manifestations in MS patients and the apparent 
fluctuation of symptoms, in absence of relapse. An example is provided by 
the Uhthoff phenomenon, characterised by a decrease in visual acuity 
following an increase in body temperature [59]. Moreover, demyelinating 
axons become sensitive to temperature increase, which worsens the 
propagation of stimuli. A 0.5°C increase suffices to induce a block in fibre 
conduction with a thin or absent layer of myelin.  
 
39 
 
In the acute stages of the disease, axonal distress caused by demyelination 
is followed by recovery of nerve conduction (remission). During this period, 
the regression of oedema and peripheral inflammatory processes cause re-
myelinating processes, and axons are once again able to conduct the nerve 
impulse and functions are restored [60].  Later, the lesion chronicises, and 
we can observe an evident reduction in the inflammatory component. The 
presence of irreversible cell damage involves constant distress of the axon. 
In turn, axonal damage results in regression of the symptoms and 
stabilisation of the neurological deficit (progressive MS), as well as a 
proportional degree of disability.  
These phenomena, which alter conduction, are important because they are 
directly correlated with clinical symptoms in MS [61].    
1.1.4 Clinical and diagnostic aspects 
 
Multiple sclerosis is a heterogeneous disease characterised by different 
clinical manifestations, which involve the visual, motor, sensory and 
autonomic systems [Table 4].  
 Symptoms Signs 
Cerebrum Cognitive impairment, 
Hemisensory and motor, 
Affective, epilepsy and focal 
cortical deficits (rare) 
 
Deficits in attention, reasoning and 
executive function (early), dementia (late) 
 
Upper motor neuron signs 
Optic Nerve Unilateral painful loss of 
vision 
Scotoma, reduced visual acuity, color 
vision and relative afferent pupillary effect 
Cerebellum and 
cerebellar pathway 
Tremor 
Clumsiness and poor 
balance 
Postural and action tremor, dysarthria 
Limb incoordination and gait ataxia 
Brainstem Diplopia, oscillopsia, 
vertigo, impaired 
swallowing, impaired 
speech and emotional 
lability, paroxisomal 
symptoms 
Nystagmus, internuclear and other 
complex ophthalmoplegias 
Dysartria 
Pseudobulbar palsy 
Spinal cord Weakness, stiffness and 
painful spasms, bladder 
Upper motor neuron signs, spasticity 
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dysfunction, erectile 
impotence, constipation 
Other Pain, fatigue, 
temperature sensitivity 
and exercise intolerance 
 
Table 4 Symptoms and sign of MS [2] 
   
The progress of MS [Figure 8] is highly variable, and is classified as 
described below. 
 Clinically isolated syndrome (CIS-MS): characterised by the 
appearance of a neurological episode (symptom or sign), which lasts 
for at least 24 hours and is due to a demyelinating process of the 
central nervous system. People with a CIS will not necessarily 
develop MS. 
 Relapsing-remitting MS (RR-MS): more common (85-90% of cases), 
it is characterised by episodes of neurological dysfunction without 
either infection or fever (relapses), followed by periods of partial or 
complete remission. Relapses are more frequent in the early stages 
of the disease. The typical symptoms observed in this form are optic 
neuritis (also occurring in 20% of cases), sensory deficits or 
cerebellar dysfunction. 
 Secondary progressive MS (SP-MS): after an initial phase of RR-MS, 
disease progression accumulates clinical impairment, either without 
or with relapses. SP-MS is characterised by a persistent disability that 
progresses gradually over time. In this form the most commonly 
observed symptoms are paresis, spasticity, and gait ataxia.  
 Primary progressive MS (PP-MS): typically presents at an older age. 
It is characterised by a worsening of neurological functions since the 
appearance of the first symptoms, without actual relapses or 
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remissions. The course is insidious with a slow increase in 
neurological disability. 
 
Figure 8. Progress of MS [2] 
 
The diagnosis of MS is based on diagnostic criteria recently reviewed and 
published by the International Committee for Multiple Sclerosis (McDonald's 
Criteria) in 2010 [Figure 9] [6,62]. The diagnosis is worded as dissemination 
of lesions in space (DIS) and time (DIT). Magnetic resonance (MRI) plays a 
key role in defining the picture of MS, but the examination of CSF and 
neurophysiologic analysis can help as well. A standardised MRI protocol has 
been proposed by MAGNIMS for clinical practice [63]. 
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Figure 9 McDonald's criteria for MS 
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Brain MRI usually reveals multifocal T2-hyperintense white matter lesions in 
juxtacortical, infratentorial and periventricular regions. Instead, in T1-
weighted images, lesions show hypointensity (Black holes) [Figure 10]. 
 
Figure 10. Typical MS lesions in the brain and spinal cord. Arrows indicate the lesions. 
(A) periventricular lesions. (B) periventricular lesions with contrast enhancement of one lesion. 
(C) juxtacortical lesions. (D) infratentorial lesions. Sagittal (E,F) and axial (G,H) scans with a 
cervical spinal cord lesion [64]. 
Sometimes, most patients need supportive evidence before an MS 
diagnosis, such CSF analysis. This includes white cell count (<25 cells per 
cm3, predominantly lymphocytes) and protein (<1 g/L), elevated IgG index 
and the absence of IgG oligoclonal bands in serum (Pattern 2). Oligoclonal 
bands (OCBs), revealed using isoelectric focusing (IEF), are found in 90% of 
MS cases, but are not specific. Indeed, they are also present in other 
neuroinflammatory disorders.  Four patterns are defined [Figure 11], namely 
Pattern 1: normal polyclonal IgG distribution in CSF and in serum; 
Pattern 2: OCBs in CSF and absence in serum; typical in MS; 
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Pattern 3: OCBs in both, CSF and serum; they indicate acute inflammatory 
processes in the CNS, such as encephalitis, with an important systemic 
component; 
Pattern 4: also called “mirror pattern”, presents OCBs in CSF and serum. 
Serum bands spread passively in the CSF compartment [65]. 
 
Figure 11. Oligoclonal band patterns [65]  
Evoked potential in auditory, sensory or visual pathways, analysed by 
neurophysiological tests, allow to identify clinically silent lesions through 
dissemination in space, thus contributing to a diagnosis of MS. They can also 
be suggestive of demyelination, but with low specificity [64]. 
Though we have good and easily applicable criteria for MS diagnosis, they 
are invasive and expensive. Moreover, differential diagnosis is difficult to 
perform today. For these reasons, further studies are required to identify 
more specific and sensible biomarkers. 
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1.1.5 Body fluid biomarkers for multiple sclerosis 
 
The diagnosis of multiple sclerosis, as previously described, is based on 
exclusion. It considers clinical evaluation and MRI analysis but, though they 
are precious, they have low specificity in the earliest stage. Hence, research 
has focused on CSF and blood as a source of dynamic, accessible and cost-
effective biomarkers. Moreover, body fluid biomarkers could be useful for a 
differential diagnosis, given the clinical heterogeneity of demyelinating 
diseases [Figure 12].  
 
Figure 12. Biomarkers in different stages of MS [66] 
Inflammatory and immunological markers 
IgG-OCBs [67], IgM-OCBs [68], IgG directed against neurotropic viruses [69] 
and the increase in chitinase-3-like protein 1 (CHI3L1) [70] are the strongest 
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inflammation markers to identify CIS converters and support early MS 
diagnosis. 
Plasma cells, besides immunoglobulin, also secrete immunoglobulin free 
light chains (FLCs), which can be detected in serum and CSF. There are two 
types of FLC, precisely kappa FLCs (k-FLC) and lambda (λ-FLC). 
Lymphocytes usually produce a small amount of excess FLCs over the heavy 
ones. These chains, which do not combine to form complete 
immunoglobulins, are released into blood, CSF and urine. Some evidence 
indicated high levels of k-FLC as a potential biomarker of CIS and RR-MS 
[71]. FLC have the advantage of being easily detectable by an automated 
nephelometric method [72].  
In a systems immunology approach that compares multiple 
immunomodulatory treatments, Dooley et al. have demonstrated a unique B 
cell pathway, including B cell activation factor (BAFF) and transitional B cells, 
as shared across treatments [73]. These data, along with those from other 
recent studies of individual treatments, indicate the key role for B cells not 
only in the pathogenesis but also in the treatment of MS [74]. In this 
framework, recent studies have reported higher CSF levels of B-cell-
attracting C-X-C motif chemokine 13 (CXCL13) in CIS converters than in 
non-converters [75]. However, CXCL13 levels are increased also in other 
inflammatory diseases of the CNS and lacks specificity.  
Among useful markers to discriminate MS and neuromielitis optica (NMO), 
we find haptoglobin, an acute phase protein produced and secreted by the 
liver when serum contains anti-myelin oligodendrocytes glycoprotein IgG 
(MOG-IgG) and anti-aquaporin 4 IgG. In particular, the discovery of these 
molecules in the serum of NMO patients allowed to define this disease as 
pathophysiologically distinct from MS [66]. 
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Axonal damage markers 
In recent years, research on biomarkers has focused on neurodegenerative 
markers. In particular, in MS neurofilaments, glial fibrillary acidic protein 
(GFAP) and N-acetyl aspartate (NAA) play a key role as axonal damage 
markers. 
Neurofilaments are the major components of the cytoskeleton axon. They 
consist of 3 different chains, namely light (NfL), intermediate and heavy 
(NfH). Following an axonal injury, these chains can be released in blood and 
CSF circulation and, in peripheral regions, and reflect neurodegenerative 
processes in the CNS. Indeed, high CSF and serum levels of Nf were found 
in patients with different neurological diseases [76,77].  
In MS, elevated neurofilaments are good candidates as axonal damage 
biomarkers [78]. Their levels in biological fluids precede global brain atrophy 
in MRI and are correlated with disability [79]. Moreover, CSF NfL seem to be 
a promising prognostic biomarker for CIS conversion [80]. However, more 
extensive validation in a large cohort of patients is required because their 
prognostic value seems limited in individual patients [66]. 
 
GFAP is a protein of the cytoskeleton of astrocytes. Increased levels of 
GFAP were measured in a progressive form of MS, and were associated with 
disability [81,82]. 
NAA is the second most concentrated molecule in the brain after the amino 
acid glutamate. Assessed using proton magnetic resonance spectroscopy, it 
has a high pathological specificity for axonal density. Its levels were low in 
CSF from SP-MS patients, compared with RR-MS and CIS. NAA is 
negatively correlated with disability and positively associated with brain 
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atrophy [66,83]. Therefore, NNA could be a marker of neurodegenerative 
processes, especially in the progressive form pf MS. 
Other markers 
Non-coding RNA, such as microRNA (miRNA) and long non-coding RNA 
(lncRNA), are being intensively investigated as a new class of biomarkers. 
They are involved in T-cell regulation and in other inflammatory pathways.  
An involvement of microRNA (miRNA) in MS pathogenesis has been 
extensively established [84], with particular regard to the dysregulation 
observed in circulating miRNA levels in CSF and serum from MS patients, 
compared with controls. In particular, some miRNAs appeared to be 
specifically dysregulated in serum or plasma of progressive patients [85–87]. 
This aspect confers miRNAs the potential to become a promising biomarker 
of disease progression or of response to therapy as with other diseases, such 
as cancer, where the employment of miRNAs as a new diagnostic tool is 
about to become an actual fact. However, the sample sizes of miRNA studies 
published are very small and a replicate in larger population is required. 
LncRNA are abundant in the CNS, and it has been hypothesised that brain 
complexity requires a large number of regulatory RNAs. Under this 
assumption, some lncRNA involved in this context have been identified and 
their dysregulation has been linked to neurological disorders, such as 
Huntington’s Disease, Alzheimer’s Disease and psychiatric disorders [88–
90].  
To date there is little evidence of lncRNA in MS; recently, three lncRNA have 
been identified as deregulated in the serum of RR-MS patients, compared to 
controls, precisely nuclear paraspeckle assembly transcript 1 (NEAT1), 
taurine upregulated 1 (TUG1), and 7SK small nuclear (RN7SK RNA) [91]. 
49 
 
Conversely, Zhang et al. identified a subset of dysregulated lncRNA in 
peripheral blood mononuclear cells (PBMCs), by microarray analysis, in a 
population consisting of 26 MS patients [92].  
Given that, this thesis investigated the role of lncRNA in MS pathogenesis by 
using a comprehensive methodological approach in order to achieve reliable 
results. 
 
Dysregulation in lncRNA and miRNA levels detected in biological fluids could 
be a new source of MS biomarkers. They could be helpful for disease 
diagnosis, prognosis and identification of clinical subtypes, thereby aiding 
therapeutic decisions or the monitoring of therapeutic effects. The discovery 
of MS biomarkers should greatly improve the diagnosis and management of 
MS and, in this context, miRNAs and lncRNAs could have great value for the 
research of new therapeutic targets [28]. 
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1.2 Long non-coding RNA (lncRNA) 
 
Until recently, the main role of RNA was thought to be that of a messenger 
that transfers information from DNA to proteins. The discovery of different 
RNA subtypes has changed the scene. 
More than 98% of human RNA is not translated into proteins, and 50-70% of 
this 98% is represented by introns. The idea that the genome exercises its 
function only through classical genes and proteins seems overly simplified, 
since a notable part of the genetic code is transcribed into RNA that is not 
converted into proteins. Many studies, in the past, focused on protein-
encoding genes, although most of the human genome is represented by non-
coding DNA, considered, in the past, as “junk” or as interfering with normal 
functions. Recent data have shown that this part of the genome is important 
and is involved both in physiological processes and in tissue homeostasis 
[93–95]. This idea is also supported by the point of view of evolution. Indeed, 
protein encoding genes have remained relatively stable, while the number of 
non-coding transcripts has increased considerably, in parallel with the 
complexity of the organism [96].  
The genome has at least 10,000 transcripts with a low or no protein-coding 
potential, and a length of more than 200 nucleotides [97]. They are called 
long non-coding RNA (lncRNA). These molecules share some common 
features with microRNA (miRNA), as they can be spliced, capped and 
polyadenylated [98]. They regulate gene expression at the epigenetic, 
transcriptional, and post-transcriptional level in cellular homeostasis [27]. 
LncRNA can be classified based on their location in genome, compared to 
protein-coding genes [Figure 13]: 
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 Intergenic (LincRNA): localised in the genomic region in which there 
are no encoding genes;  
 Genic: associated with other transcripts; they are divided into: 
 Exonic: lncRNA exon intersects a part of protein-coding locus 
on the same (sense, S) or on the opposite strand (antisense, 
AS); 
 Intronic: they reside within introns of a coding gene, but do not 
intersect any exons; 
 Overlapping: they contain a coding gene within an intron on 
the same strand. 
However, there is a large number of lncRNAs with particular characteristics 
that cannot be classified using this criterion. Many lncRNAs can act as 
transcripts for small RNA production, so the previous classification may be 
ambiguous. They are, therefore, subdivided according to their functions into 
lncRNA-activated genes, pseudo-genes associated with telomeres 
(TERRA), ultra-conserved transcripted regions (T-UCR), enhancer RNA 
(eRNAs), circulars, and others [99,100]. 
 
Figure 13. LncRNA classification [100] 
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1.2.1 Biogenesis  
 
The lncRNA biogenesis resembles that of mRNAs and other non-coding 
RNA classes. They are subjected to post-transcriptional and inter/ intra-
cellular transport. Most of them have a nuclear localisation, different 
expression and low levels of conserved sequences. These molecules are 
different from coding RNA because they lack a substantial open reading 
frame (ORF) and fail to produce protein [95]. 
Usually, lncRNA is transcribed by RNA polymerase II, can be polyadenylated 
and can be spliced with the formation of different isoforms. Only a small 
number of non-polyadenylated lncRNAs are expressed by promoters of 
polymerases III. Alternatively, some lncRNA are formed by excision during 
splicing and production of small nucleolar RNA [101,102]. Since lncRNA are 
involved in chromatin and epigenetic regulation of gene expression, they are 
preferentially located in the nucleus, in contrast to mRNA, which is conveyed 
to the cytosol for translation [94,97].  
Once transcribed, they are folded into a secondary structure, which is 
guaranteed by their particular properties. For instance, the presence of 
multiple sites for hydrogen bonds enables them to adopt a 
thermodynamically more stable structure. They have many binding domains 
and are able to form double helix, pseudo-knocks, bulges or hairpin 
conformations. The resulting architecture consists in co-axial stacks of 
helices arranged in parallel or perpendicular to each other with repeated 
motifs. This structure gives them a high degree of stability.  
Although lncRNA can acquire a tertiary structure and molecular complexes, 
we currently lack data about it. There is no data about whether they can form 
ribonucleoprotein complexes (RNPs) or whether they exist as isolated RNAs. 
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Some evidence suggests that they participate in a subcellular structure 
formation called “paraspeckles”, but new structural studies are necessary to 
clarify lncRNA conformations in detail  [103]. 
1.2.2 Main functions and mechanism of action 
Though in the recent years much evidence has suggested the important role 
of lncRNA in gene expression regulation and more besides, only a small 
number has been well characterised. Some of these are involved in biological 
processes that have not been fully understood so far. The main biological 
functions of lncRNA include epigenetic regulation, chromatin remodelling 
and protein metabolism control. They can act at the transcriptional and post-
transcriptional level, and are dynamically expressed during cellular 
differentiation and development. They are able to regulate cell cycle, genetic 
imprinting and stem cell reprogramming. Summarising, we can attribute 
lncRNA to 3 main processes, precisely chromatin modification, 
transcriptional and post-transcriptional regulation [104–108] [Figure 14]. 
 
Figure 14. LncRNA functions [108] 
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Chromatin remodelling 
LncRNA interact with chromatin-modifying complexes and histone-modifying 
enzymes, and may convey them to a specific genomic locus and influence 
chromatin status. They can be involved in global epigenetic reprogramming 
and during cell growth and development. 
 In particular, some of them bind the repressive complex Polycomb 2 (PRC2), 
e.g., HOTAIR or XIST (X-inactive specific transcript). Another epigenetic 
complex associated with lncRNA is the G9a methyltransferase, related with 
Air [109]. The lncRNAs might regulate the three-dimensional structure of 
chromosomes because they facilitate the interaction between chromosomal 
loci and recruiting factors involved in gene activation. This role is played, for 
instance, by MISTRAL and HOTTIP [110].  
Recent evidence suggests the specific involvement of lncRNA, also in 
imprinting processes. X chromosome inactivation is mediated by XIST. XIST 
and Tsix anneal seem to form an RNA duplex, processed by Dicer to 
generate a small interfering RNA that inactivates the X chromosome [111]. 
Transcriptional regulation 
Transcriptional regulation can be implemented at different levels and by 
specific mechanisms.  
LncRNA can regulate neighbouring genes in cis in a sequence-independent 
manner by inhibiting the assembly of RNA polymerase II (RNApII) and 
transcription factors (TFs). Moreover, they can influence RNApII activity by 
interacting with the initiation complex, and influence the promoter’s choice. 
An example can be found in the Dihydrofolate reductase (DHFR) locus, 
where a triplex in the promoter prevents TFIID binding. 
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Sometimes, lncRNA might prevent TFs translocation to nucleus. NRON 
provides an interesting example. It is an lncRNA repressor of the nuclear 
factor of activated T cells (NFAT), which interacts with members of the 
importin beta superfamily and acts as specific regulator of NFAT nuclear 
trafficking [112].  
These RNAs might also act as co-factors or, as in the case of cyclin D1, 
tethered to the gene, they recruit TLS to modulate histone acetyltransferase 
activity of CBP and p300 and repress its transcription [111].  
Post-transcriptional regulation 
LncRNA play a key role also in post-transcriptional events, such as mRNA 
splicing, editing, transport, translation and degradation. These functions are 
possible because they can recognise complementary sequences and 
interact with mRNA.  
In particular, antisense molecules can mask some sites, forming RNA 
duplexes. It is the case of BACE1-AS, which may prevent translational 
repression of BACE1 mRNA by miR-485-5p by masking the binding site for 
microRNA [113]. 
Alternatively, lncRNA can be associated to a splicing complex and regulate 
alternative splicing. For example, GOMAFU/MIAT can bind the splicing factor 
1 (SF1) protein through its UACUAAC repeat sequences and inhibit splicing 
and spliceosomal complex formation [114]. Also MALAT1 has been found to 
regulate alternative splicing of endogenous target genes [115]. 
Finally, they can interact synergistically with miRNA and the silencing 
complex. 
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Mechanism of action 
LncRNA expression is specific for cell types and responds to different stimuli. 
This suggests that they too are under transcriptional control. Hence the 
theory that they act as signal molecules [Figure 15 I]. Indeed, this type of 
lncRNA is transcribed at a specific time to integrate the answer to 
environmental or cellular changes. Some signal lncRNAs play an active role 
in transcription, while others are merely produced. Their transcription is 
regulatory, and guarantees rapid and performing events. In this archetype 
we find XIST, HOTAIR and Air. 
Another mechanism of action of these 
molecules is that they act as a decoy. In 
this case, lncRNA titrate transcription 
factors away from chromatin. In addition, 
they can do the same for other protein 
factors, leading them into nuclear 
subdomains [Figure 15 II]. TERRA RNA 
belong to this class. 
Alternatively, lncRNA can change gene 
expression, into cis and trans, by 
recruiting chromatin-modifying enzymes 
and, as a guide, target genes [Figure 15 
III]. It is difficult to identify by the lncRNA 
sequence, which of them has this 
capability. However, it seems that 
COLDAIR, HOTTIP and Jpx work in this 
manner. 
Figure 15 Mechanisms of action [101] 
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Lastly, they are able to bring together multiple proteins and form 
ribonucleoprotein complexes (RNP). On the one hand, lncRNA-RNP bring 
histone modifications and chromatin remodelling, and on the other hand this 
scaffold stabilises signalling complexes and structures in the nucleus [Figure 
15 IV]. A ANRIL is an lncRNA scaffold [101]. 
1.2.3 Role of lncRNA in the CNS 
The functions of the vast majority of known lncRNAs appear correlated with 
the CNS. Some evidence underscored that they are expressed in specific 
neuroanatomical regions, cell types or subcellular brain compartments, and 
are involved in important neurobiological processes. This suggests that their 
deregulation can contribute to the pathogenesis of neurological disorders. 
They play a role in brain development and neurogenesis, in neural cell 
differentiation, in synaptic plasticity, in stress response and in aging 
[104,116]. 
Brain development and neural cell differentiation 
Some studies showed that lncRNA are critical regulators of neurogenesis. 
Human-induced pluripotent stem cells (iPSCs) and human embryonic stem 
cells (ES) present a dynamic expression of these molecules during neuronal 
differentiation. In particular, the 3 main players in these events are SUZ12, 
REST and SOX2OT. SUZ12 is a component of PRC2 and REST, and 
SOX2OT are the pluripotency-associated TFs [116]. These ncRNAs interact 
with protein components of chromatin-modifying complexes and allow to 
maintain ES features.    
Multipotent neural stem cells (NCS) can differentiate to form neurons and 
glia, and lncRNA are differentially expressed in the two lineages. In 
particular, neurons express TUG1, MALAT1, RIAN, GTL2 etc., while glia 
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express GOMAFU/MIAT, SOX8OT, DLEU2, etc., as shown in Figure 16. 
GOMAFU is particularly interesting, as it shows dynamic regulation during 
differentiation of neural stem cells into oligodendrocytes [117]. 
 
Figure 16. LncRNA in neural/glial differentiation [116] 
 
 Synaptic plasticity 
Recent evidence showed that lncRNA are involved in synaptic plasticity 
processes, in the development of the postsynaptic dendritic compartment, 
and in the regulation of serine/arginine-related splicing factors that influence 
synapse density. MALAT-1 is the most studied in this contest. It is present 
especially in hippocampal neurons, and regulates synaptogenesis through 
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gene splicing [118]. Other long non-coding RNA are transcribed by genomic 
loci and are involved in these processes, i.e., loci for Calmodulin/Calcium- 
dependent neurogranin and kinase inhibitor II. 
These RNAs can be associated to plasticity-related pathologies, such as 
autism and intractable epilepsy. For instance, BC1/BC200 and Evf2 
modulate neural plasticity and excitability [96,119]. Moreover, the analysis of 
some human biopsies revealed that there is an accumulation in the nucleus 
accumbens of heroin, cocaine and alcoholic-addicted subjects; therefore, 
they seem to be associated with drug dependence. Many lncRNAs are also 
associated with genes involved in the synaptic connection’s long-term 
potentiation and in short-term memory consolidation [96]. 
Ageing 
As previously described, lncRNA are implicated in development and in  brain 
ageing processes. Indeed, downregulated transcripts in ageing have a role 
in such pathways. In particular, there is a 60% decrease in BC200 levels in 
the atrophic cortex [120]. Neuronal ageing seems correlated with the ageing 
of stem cells, a phenomenon that leads to a reduced capability for self-
renewal, proliferation and differentiation with subsequent activation of 
senescence and apoptotic pathways. For this reason, lncRNA might play a 
key role in brain ageing. This hypothesis is also supported by their 
involvement in neurodegenerative diseases, typically occurring in the elderly, 
such as Alzheimer’s disease [121]. 
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1.2.4 Role of lncRNA in the immune system 
LncRNA influences a variety of functions from innate to activation of the 
adaptive immune system. Development of the autoimmune system is 
associated with an epigenetic mechanism in response to complex 
environmental changes.  
The development of immune cells from hematopoietic stem cells and their 
cell proliferation needs specific lncRNAs as regulators, and which thus 
participate in the differentiation [Figure 17] [122,123]. 
 
Figure 17. lncRNA in the immune system [123] 
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LncRNA in innate immunity 
 
The first line of defence against pathogens is innate immunity. There is a 
growing list of lncRNAs involved in the process, particularly phagocytes. 
Bacterial or exogenous proteins can significantly change lncRNA expression 
through Toll-like receptor (TLR) pathways. They regulate the innate response 
in this manner.  
In this contest, one of most important lncRNAs is lincRNA-Cox2, which acts 
as a regulator in macrophages. Indeed, its transcription is activated by TLR 
ligands and microbial pathogens, and is the last step of a complex pathway 
involving MyD88 and NF-kB. LincRNA-Cox2 is a repressor for several genes, 
such as chemokines and other inflammatory molecules, and activator for 
others (IL6) [124,125]. 
 
PACER, instead, seems to be solely involved in controlling COX-2 
expression in epithelial and monocyte cells. It is able to bind NF-kB dimer 
p50/p50, preventing the bond with the Cox-2 promoter. Hence, the 
transcription complex can be assembled, and Cox-2 expression is favoured 
[126]. 
 
Instead, during HSV-1 infection, NEAT1, the main structural RNA in 
paraspeckles, has been linked to IL-8 expression. Moreover, it regulates HIV-
1 controlling HIV-1 mRNA trafficking from nucleus to cytosol [125,127]. 
 
Cui et al. hypothesised that Lnc-IL7R could negatively regulate the 
expression of proinflammatory mediators, such as E-selectin, VCAM-1, IL-6 
and IL-8, and the subsequent recruitment of TLR4. It acts probably through 
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trimethylation of H3 actin at lysine level 27, at the proximal level of 
inflammatory mediators [128]. 
 
Lethe and THRIL, together with the molecules described, are some 
examples in the large number of lncRNA implicated in innate immunity. 
 
LncRNA in adaptive immunity 
 
It is a known fact that lymphocytes T and B, which represent the mediators 
of adaptive immunity, differentially express lncRNA. In addition, also subsets 
(Th1, Th2, Th17, Treg) present a specific expression pattern. This underscores 
the importance of lncRNA also in immune cell differentiation. 
Some important lncRNA expressed by T cells are NRON, GAS5 and LincR-
Ccr2-5'AS. 
 
NRON is an intronic lncRNA repressor of NFAT, a calmodulin/Ca2+ 
dependent TF that governs the expression of different cytokines, such as IL2. 
NRON, acting as a scaffold and interacting with β-importins, regulates NFAT 
translocation from cytoplasm to nucleus [124,129,130].  
GAS5, instead, is an important repressor of T cell proliferation. Indeed, it has 
been linked to cell-cycle arrest in response to deprivation or other 
environmental conditions. GAS5 also regulate glucocorticoid receptor 
expression [131,132].   
LincR-Ccr2-5'AS plays a role in Th2 CD4+, timocyte and mature peripheral T 
cell migration. So far, these data are from mice and must be confirmed in 
humans. 
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Regarding B cells, whether lncRNA have an important role in their maturation 
and function remains an open question. In comparison to T cells, very little 
knowledge of B cell function of lncRNAs is known [124,125]. 
1.2.5 Long non-coding and multiple sclerosis  
lncRNA are good candidates as diagnostic and prognostic markers in 
autoimmune, inflammatory and neurodegenerative diseases as a result of 
their potential role in the pathogenic mechanisms. As demonstrated for 
miRNAs, the deregulation of some lncRNA is now recognised as a distinctive 
feature of some diseases. Among them, oncological and neurological 
diseases are the most investigated fields [89,130,133,134]. However, to 
date, research is only at the beginning, and there is a very little information 
about the role of lncRNA in multiple sclerosis. 
 
As described above, adaptive immunity plays a key role in MS pathogenesis, 
and at molecular levels immune cell functions are modulated by lncRNA. Not 
only immune processes but also neurodegeneration is implicated in MS, 
suggesting the involvement of lncRNA in these processes. 
 
In 2008 Burfoot et al. described HLA-A*2 and A*3 loci as protective against 
MS. Several lncRNA genes are located in these genomic regions, such as 
IL2RA locus. Among them, M21981 is upregulated in activated T cells 
[135,136]. 
FNG-AS1 (Tmevpg1), instead, is an lncRNA that is able to regulate T 
lymphocytes, and it is considered involved in MS because of the TMEV 
infection that is often used as an experimental murine model for MS [135]. 
Moreover, it is transcribed by a cluster of genes for cytokines, including IFNγ. 
Indeed, FNG-AS1 is adjacent and appears to promote its expression [137]. 
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In 2016 Zhang et al. were the first researchers to investigate the expression 
profile of lncRNA in peripheral blood mononuclear cells (PBMCs). Using 
microarray analysis they found 2,353 upregulated lncRNAs and 389 
downregulated lncRNAs in 26 MS patients, compared to healthy control 
subjects. Different pathogenic pathways, among immune and 
neurodegenerative ones, are involved in this large global de-regulation [92]. 
 
That same year, Santoro et al. identified three lncRNAs as deregulated in the 
serum of RR-MS patients, compared to controls precisely nuclear 
paraspeckle assembly transcript 1 (NEAT1), taurine upregulated 1 (TUG1), 
and 7SK small nuclear (RN7SK RNA). These molecules are important 
players in neurodegeneration processes. However, the number of samples 
was small and these data need validation [91] . 
The most recent paper published early in 2017 reports that, in a cohort of MS 
patients, the expression of lnc-IL-7R long non-coding RNA correlates with 
soluble and membrane-bound isoforms of IL-7Ra gene. However, there are 
some significant differences between the expression levels of IL-7RB, IL-
7RS and lnc-IL-7R genes in cases and controls. Of course, we need 
additional studies to highlight IL7 regulation [138]. 
This thesis focuses on this field of research to investigate the role of cellular 
lncRNA in MS pathogenesis by using a comprehensive methodological 
approach to achieve reliable results. 
  
65 
 
1.3 Exosomes  
Early studies on exosomes date back to the ‘80s, when Trams et al. noticed 
neoplastic cell line capacity to release microvesicles containing 5’-
nucleotidase activity [139]. Later, electron microscopy enabled researchers 
to observe that, in reticulocyte cultures, multivesicular endosomes could 
merge with the plasma membrane, which internalised their content. By 
centrifugation of the supernatant, they isolated these vesicles and called 
them “exosomes”. 
Exosomes are small membrane vesicles, which can be detected in biological 
fluids (serum, plasma, CSF, urine, etc.…) secreted by different cell types. 
The exosome diameter is 30-100 nm, and their density range in a sucrose 
gradient ranges from 1.13 to 1.19 g/mL. These vesicles present a 
characteristic “cup-shaped” morphology, a phospholipid bilayer containing 
high levels of cholesterol, sphingomyelin and ceramide with a specific 
membrane-micro domain, called “lipid rafts” [140,141]. 
The exosome membrane is characterised by the proteins involved in 
transport and membrane fusion, such as Rab, GTPase, Annexine and 
Flotillin, by the components of the ESCRT complex, including Alix, Tsg101 
and HSP, integrins and tetraspanines, besides CD9, CD63, CD81. It is 
interesting to note that their surface can also have the markers of original 
cells. In particular, neural-derived exosomes present L1CAM (i.e., CD171) 
and NCAM [141–143].  
The following paragraphs will outline biogenesis, molecular composition and 
main functions of exosomes. 
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1.3.1  Biogenesis and secretion   
The biogenesis of exosomes begins with the formation of endocytic vesicles 
from specialised regions of the plasma membrane. This process can be 
clathrine-dependent, such as for the transferrin receptor, or clathrine-
independent, as for GPI-anchored proteins.  
Exosome formation involves the production of intraluminal vesicles (ILVs) 
within the multivariate bodies (MVBs). The pathways are illustrated in Figure 
18. 
The Endosomal Sorting Complexes Required for Transport (ESCRT) 
dependent biogenesis have the ESCRT complex as main player. In 
particular, the subunit ESCR-0 recognises ubiquitinated proteins in the 
cytosolic side of MVB, separates them into micro domains and then binds 
ESCRT-I. Later, the recruitment of ESCR-II entails RNA and protein transport 
within the vesicles that form. ESCR-III arrival completes the ESCRT-complex 
formation, following which ILV originate. Then, ubiquitin and ESCRT are 
recycled in the cytosol, and the free exosomes are secreted into extracellular 
space. 
Not all exosomes form in this manner. Indeed, there is an alternative ESCRT- 
independent route. In this case, sphingomyelinases form the ceramide from 
a machine, presenting raft-based micro domains rich in sphingolipids, which 
triggers ILVs formation within the MVBs. 
The MVBs destiny has two possibilities, namely to melt with lysosomes and 
degrade their content or melt with the plasma membrane and release ILVs 
into the extracellular environment [144]. 
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Figure 18. Exosome biogenesis [144] 
 
Alternatively, exosomes originate by the “direct pathway”. T cells and 
leukemic cell lines release exosomes directly from their plasma membrane. 
These vesicles cannot be distinguished from exosomes formed by the classic 
endosomal pathway because they are enriched with classical exosome 
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markers, such as CD63 and CD81, and have similar diameters and densities 
[145].  
After ILVs formation within the MVBs, they are released into the extracellular 
environment through different steps, namely transport, binding and fusion 
with the plasma membrane.  
Annexins and Rab family proteins mainly mediate transport and binding 
processes.  
Annexins are proteins located in the cytosol and characterised by a 
phospholipid binding domain and regulated by Ca2+.   
Instead, Rabs are monomeric G proteins anchored to a cell membrane. Like 
other GTPases, they switch between two conformations, precisely an 
inactive form bound to guanosine diphosphate (GDP), and an active form 
bound to guanosine triphosphate (GTP). A GDP/GTP exchange factor (GEF) 
catalyses conversion from the GDP-bound to the GTP-bound form, thereby 
activating the Rabs. Rab effectors are heterogeneous, and different isoforms 
have different roles; for instance, RAB5 associates with early endosomes, 
RAB7 with late ones and RAB11 is implicated in recycling processes [146]. 
An important isoform is RAB27A. It controls exosome binding and the 
secretion of soluble factors during the following steps of exosome release, in 
stressful conditions.  
Fusion events seem to be determined by soluble factors, such as soluble 
NSF-attachment protein (SNAP) and membrane complexes, SNAP-
attachment protein receptor (SNARE), formed by VAMP-7 and VAMP-8. 
These are also involved in lysosomal vesicles fusion processes, but how they 
contribute to exosome secretion is still unknown at present [141,144,147].  
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1.3.2 Content 
According to the exosome content database “Exocarta” (www.exocarta.org), 
286 studies identified 9,769 proteins, 1,116 lipids, 4,946 mRNAs, 2,838 
miRNA, and about 10 lncRNAs in exosomes derived from different cell types. 
This further underscores their complexity [Figure 19]. 
 
Figure 19. Exosome content [148] 
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Proteins 
Both ubiquitous and cell-specific proteins can be transported by exosomes.  
Proteins involved in exosome biogenesis, such as Rab family and annexins 
(I, II, V, VI), are constitutively present in them, along with some proteins that 
have unknown common functions. Among them, we can find cytosolic and 
cytoskeletal components, for instance actin and tubulin, receptors, and 
proteins involved in signal transduction, such as kinases as G proteins. 
Metabolic enzymes, pro/anti apoptotic and heat-shock proteins, which 
regulate the trafficking of misfolded proteins to degradation, are present as 
well.  
Several adhesion molecules have been identified, such as intercellular 
adhesin molecule-1, CD146, CD9, milk-fat globules, EGF-factor VIII (MFG-
E8), CD18, CD11a, CD11b, CD11c, CD166 and LFA-3 / CD58. 
Tetraspanines are the most typical exosome proteins. They are a family of 
transmembrane proteins, which seems involved in the formation of 
multimeric protein networks. Since the exosome membrane is enriched with 
them, including CD9, CD63, CD81 and CD82, they can be considered as a 
subject’s own exosome markers [141,143,146,149,150].  
Exosomes also transport specific proteins for various parent cell types. For 
instance, MHC class II is present in vesicles derived from APC, CD86, and 
large amounts of several integrins are present, if DCs are the parent cells. In 
CND-derived exosomes, characterised by L1CAM (CD171) marker, we find 
the amyloid β, Tau and α-synuclein proteins [151–153]. This is important 
because it guarantees identification of the original cell type, with a possible 
link with pathological conditions states, and probably addresses them to a 
target cells.  
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Lipid 
Limited data are available regarding lipid composition. 
As with proteins, the lipid content of exosomes reflects the original parent 
cell. However, the lipid amount is higher in vesicles, which explains the 
higher rigidity of their membrane, in comparison with the plasma membrane 
of the cell. 
Exosomes are enriched in cholesterol, diglycerides, sphingolipids, such as 
sphingomyelin and ceramide involved in a biogenesis pathway. Furthermore, 
they present phospholipids and glycerol-phospholipids, including 
phosphatidylcholine, phosphatidylserine, phosphatydyl-ethanolamide and 
phosphatydyl-inositol [154].  
Nucleic Acids 
RNA can be circulating in different modes, precisely cell-free, bound in 
protein complexes or packed in microvesicles. The presence of functional 
RNA in extracellular vesicles was described for the first time in mice stem 
cells by Ratajczak et al. in 2006 [155].  
Unlike cellular mRNA, which has a length of 400-12,000 nucleotides, 
exosomal mRNA is long <700 nucleotides. It could be either intact or in 
fragments [156,157]. 
There are also mRNA, miRNA [158], lncRNA [159–161], t-RNA, snoRNA, 
snRNA [161], vault-RNA and Y-RNA [161]. Some evidence reports the 
absence of r-RNA, 18S and 28S, which is abundant in cells [156]. 
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These RNA molecules play a key role in the regulation of gene expression, 
influencing cellular pathways and functions not only between cells of the 
same tissue but also between different tissues [156]. This method is efficient 
when there is an external stimulus and the answer must be obtained quite 
rapidly. There are few studies about DNA content in exosomes; therefore, 
this aspect needs to be explored in-depth.   
1.3.3 Uptake 
Exosomes interact with the target cell in different ways [Figure 20]. 
 
Figure 20. Exosome uptake [162] modified 
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Soluble signalling involves the proteolytic cleavage of ligands from the 
exosomal surface or alternative splicing, unlike juxtacrine signalling that 
requires the juxtaposition of ligands and receptors on the surfaces of both 
the exosome and the target cell. The membrane bond is mediated by FasL, 
TRAIL and TNF that can be cleaved by metalloproteinases to form soluble 
cytokines. 
Exosomes could also be internalised by fusion. During this process, vesicles 
merge with the cell membrane, but the effective mechanism is still unknown. 
Alternatively, exosomes are taken up by means of phagocytic events. It is an 
actin-mediated mechanism that requires opsonisation of vesicles and the 
presence of specific receptors, such as FcRs, on the cell surface. This 
process is dependent on actin, PI3K and dynamin 2.  
Another uptake mode is macropinocytosis. In this case, the plasma 
membrane creates protrusions with actin filaments, with the subsequent 
formation of an invagination, which incorporates the particles. Exosome 
macropinocytosis is dependent on Na+ and PI3K.  
Finally, we have two endocytosis processes mediated by receptors or by raft. 
The first, also called clathrin-mediated endocytosis, requires clathrin and 
adaptor protein complexes. The second one is caveolae-mediated 
endocytosis regulated by distinct combinations of dynamin, flotillin and/or 
Rab proteins [162]. 
Due to the lack information about exosome uptake, further studies are 
required to better understand cell-to-cell communication mediated by these 
vesicles. 
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1.3.4 Biological functions in the CNS and in the immune system 
As mentioned in the description of exosome biogenesis, they would be an 
alternative to lysosomal degradation. Indeed, proteins resistant to some 
proteases might be eliminated through this pathway. 
However, the most important role of these vesicles is cell-to-cell 
communication. Obviously, in order to mediate any kind of biological function, 
exosomes must transfer their content into the target cell.  
Recent studies suggest that they are capable of stimulating receptors located 
on the target cell membrane by releasing specific ligands. Moreover, it seems 
that they are able to transfer superficial receptors from cell to cell, and to 
change their cell surface distribution with the consequent influence on 
cellular metabolism and function [163]. 
As cargo molecules, they can transport enzymes, infectious agents [164], 
organelles, such as mitochondria [165] and growth factors, and control 
differentiation and proliferation pathways [141]. 
Exosomes are also actively synthetised during oxidative stress, irradiation 
and hypoxia events [166].  
There is evidence of a possible role of these vesicles in neurodegenerative 
and immune-mediated disorders, such as multiple sclerosis 
[144,152,163,167,168]. 
The role of exosomes in the CNS 
In the CNS, exosomes occur during normal development and physiology, 
acting as mediators of intercellular communication and playing functional 
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roles not only during development but also during normal neuronal 
regeneration.  
First, in 2011 Lachenal et al. explained the role of exosomes in normal CNS 
physiology. They demonstrated how Ca2+ and glutamatergic synaptic activity 
influence exosome secretion from hippocampal and cortical neurons [169].  
A few years later, Frühbeis et al reported an important reciprocal 
communication between neurons and oligodendrocytes mediated by these 
vesicles. Oligodendrocytes release exosomes in response to neuronal stress 
signals, and they are internalised along the endocytic pathway. In neurons, 
they release proteins, glycolytic enzymes, mRNAs and miRNAs to axons with 
a neuroprotective function [170]. Not only oligodendrocytes, but also other 
microglial cells and astrocytes communicate with exosomes  that use 
neurons [171]. 
Exosomes play a crucial role also in synaptic plasticity and during myelin 
membrane biogenesis [172]. 
Regarding synaptic plasticity, exosomes allow the transport of proteins, 
mRNAs and miRNAs from the postsynaptic terminal to the presynaptic 
terminal [173]. In addition, inverse transport occurs through sinaptotagmine-
4 (Syt-4), a transmembrane protein of synaptic vesicles. Korkut et al. 
reported that Syt-4 is present in presynaptic exosomes, and since Syt-4 is 
essential for retrograde signalling, this transport is an integral part of 
presynaptic control [174]. Moreover, MVB fusion with the plasma membrane 
is related to synaptic activity, supporting the role of these vesicles in synaptic 
plasticity [175]. 
76 
 
It was observed that, during myelin membrane biogenesis, exosomes have 
a regulatory function between glial cells and axons. On the one hand they 
contribute to the elimination of excess membrane [170], and on the other 
hand they are involved in the biogenesis of the membrane itself [176]. 
The role of exosomes in the immune system 
The immune response, both adaptive and innate, is included in the large 
number of biological functions of exosomes.  
A highly significant role played by exosomes is induction and promotion of 
the adaptive immune response. Extensive data showed the role of exosomes 
in T and B cell activation, also related to DC.  
It is widely known that antigen (Ag) presentation to T cells is mediated by 
APC. Recent studies showed that this happens not only directly, but also 
through co-stimulatory signals issued by exosomes secreted by APC. 
Furthermore Sprent et al. 2005 demonstrated that these vesicles express 
MHC class I, B7 and ICAM1, molecules that can activate CD8+ T cells also 
in the absence of APC [177]. This feature is important in the CNS, an 
immunologically-privileged organ with limited MHC molecule expression.  
Exosomes might also downregulate adaptive immunity, inhibiting T and B 
cells. They can act on myeloid cell precursors or, as in the case of tumours, 
increase TGF-β1 expression. In addition, a direct immunosuppressive effect 
is involved in the development of immune tolerance. These events have DC 
as main players. Indeed, mast cells secrete exosomes that are able to 
regulate the expression of MHC II, CD80, CD86 and CD40 in DC [178].  
In innate immunity, instead, exosomes participate in chemotaxis events. For 
example, vesicles secreted by platelets act as cargo for chemotactic factors, 
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such as sphingosine-phosphate and arachidonic acid, and exert their 
function on NK cells, monocytes, T and B cells [179]. 
Exosomes are also involved in TLR-mediated processes. In the CNS, TLR7 
can be stimulated by Letc and miRNA 21, transported by vesicles, and 
modify neuronal growth. Moreover, they control cytokine expression in 
PBMC through these receptors [163]. 
Overall, these observations suggest the existence of a specific signalling 
mechanism between immune cells and other target tissues mediated by 
microvesicles. 
1.3.5 The role of exosome in multiple sclerosis 
As previously described, exosomes play an important regulatory role in SNC 
and in immune system. Therefore, it’s not surprising that recently, a large 
number of study has been focused on their involvement in 
neurodegenerative and autoimmune disease, such as MS. 
As reported in the previous paragraph, myelination processes include cell-
to-cell communication mediated by microvesicles. In particular, 
oligodendrocytes secrete exosomes, under neuronal influence, and delay 
myelin formation during CNS development. On the other hand, DC-derived 
exosomes promote oligodendrocyte growth and increase myelination, 
promoting repair events. This evidence underscores the possible importance 
of these vesicles in the regeneration process of damaged myelin sheaths, 
when there is neuronal stress associated with disease pathogenesis 
[170,171,180].  
Another important mechanism in MS pathogenesis is related to the 
transmigration of exosomes through capability BBB immune cells. Activated 
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lymphocytes, monocytes, platelet and endothelial cells too might secrete 
vesicles, the content of which increases trafficking through BBB, sustaining 
proinflammatory processes. 
It seems that endothelial cell-derived exosomes transfer the ICAM-1 
receptor, namely integrin Mac-1, to monocytes. Moreover, those derived 
from T cells stimulate their expression, enhancing their transmigratory ability 
[163,181]. Along with these aspects, it is interesting to note that vesicles 
released by platelets too promote BBB trafficking. Indeed, within them 
researchers found high levels of P-selectin, which by interacting with PSGL1 
and PECAM-1 increase the expression of integrin α4-β1 on T cells [163,182].  
The facilitated transmigration of proinflammatory cells through the BBB, 
supported by microvesicles, favours and maintains pathogenic MS 
processes.  
Given the above evidence, in recent times attention has focused on the 
possibility of considering exosomes and their cargo as potential MS 
biomarkers. The discovery of an association between their content and 
disease activity, the capability of select specific neural-derived vesicles, as 
well as accessibility in biologic fluids make exosomes an attractive candidate 
as biomarkers for various disease, in this case for MS. 
For instance, Saenz-Cuesta et al, noticed a general increase in exosomes 
present in serum and CSF of MS patients, especially in the RR-MS form, 
during relapses [183]. Moreover, Verderio et al. 2012 showed how a higher 
amount of myeloid-derived vesicles in CSF from MS patients was associated 
with the inflammatory stage and correlated with MRI lesion data [184]. These 
are just two studies, but they might support the possible role of exosomes as 
promising biomarkers.  
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Nevertheless, very little data is published in the Literature, and more studies 
are required to confirm the feasibility of exosomes and their cargo as 
biomarkers. 
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2. AIM AND STUDY DESIGN 
 
The aim of this study was to identify a specific signature of long non-coding 
(lnc) RNA expression in Peripheral Blood Mononuclear Cells (PBMCs) and 
in neural-derived exosomes from patients with multiple sclerosis (MS), 
compared to healthy controls, to determine the role of these transcripts in 
disease pathogenesis, and also to investigate their possible use as 
biomarkers of MS susceptibility and progression. 
LncRNA represents a class of non-coding transcripts, whose functional 
importance has recently emerged in many diseases, including neurological 
disorders. LncRNAs are highly expressed in the CNS and in the immune 
system, where they are involved in crucial physiological processes. The 
discovery of an alteration in transcripts involved in some of these specific 
processes sheds light on partially known or entirely new aetiopathogenic 
mechanisms. 
Interestingly, a part of exosome cargo is made up of miRNA and lncRNA, 
which could be considered possible disease-specific markers themselves. 
Within exosomes, lncRNA are well protected and transported for long 
distances from parental cells to other targets. Therefore, we could identify an 
ideal biomarker in the periphery that reflects the pathogenic status of the 
CNS, which could reveal disease progression and activity, as well as 
contribute to the choice of therapy. 
Given these premises, we investigated the role of cellular and exosomal 
lncRNA in MS pathogenesis by using a comprehensive methodological 
approach in order to achieve reliable results.  
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To this end, we initially performed an exploratory analysis by using specific 
arrays that led to screen 90 lncRNAs involved in autoimmunity and in the 
human inflammatory response, related to disease status, in PBMC from 10 
MS patients in order to identify the dysregulated ones. The additional 
validation step was designed to validate best hits lncRNAs in a larger 
population consisting of 30 cases and 25 controls, and by using specific 
Taqman probes for the quantitative real-time PCR assay. Lastly, a replication 
step was performed in an independent Belgian cohort consisting of 24 cases 
and 23 controls, with the droplet digital PCR system [Figure 21]. 
 
Figure 21. Study design for lncRNA from PBMC analysis 
 
In parallel, we investigated lncRNA expression levels in neural-derived 
exosomes from the serum of MS patients, in comparison with healthy 
controls. We tuned the exosome extraction protocol, then we characterised 
them morphologically by using Transmission Electron Microscopy (TEM) and 
by citofluorimetry considering surface markers. Once neural-derived 
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exosomes had been isolated, we extracted lncRNAs and analysed their 
expression using specific arrays in RT-PCR [Figure 24]. 
 
Figure 22. Study design for exosomal lncRNA analysis 
. 
Lastly, we analysed the cellular and exosomal lncRNA profile, correlating 
them, when possible, with clinical aspects. 
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3. MATERIALS AND METHODS 
 
3.1 Long non-coding expression profile in peripheral blood 
mononuclear cells from multiple sclerosis patients 
3.1.1 Population and sample collection 
Three cohorts of MS patients were recruited and their characteristics are 
summarised in the Table 5.  
 Controls MS-all RR-MS PP-MS 
Italian discovery 
population 
    
N 6 10 5 5 
Gender (M:F) 2:4 2:8 1:4 1:4 
Mean age at onset, 
years±SD 
35.4±2.9 37.5±5.8 36.8±1.7 45.5±2.0 
Italian validation 
population 
    
N 25 30 22 8 
Gender (M:F) 13:12 12:18 9:13 3:5 
Mean age, years±SD 33.9±12.7 47.6±10.8 44.4±9.4 53.7±10.5 
Mean age at onset, 
years±SD 
NA 33.1±11.19 31.1±11.0 41.2±7.3 
Mean disease duration, 
years±SD 
NA 12.3±8.4 12.3±8.9 10.8±6.0 
Median EDSS (range) NA 2 (0-7) 1.5 (0-5) 
6 (3-7) 
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Belgian replication 
population 
    
N 23 24 17 7 
Gender (M:F) 11:12 6:18 2:15 4:3 
Mean age, years±SD 51.5±19.0 51.5±21.5 49.5±22.3 51.5±21.5 
Mean age at onset, 
years±SD 
NA 20.1±24.3 36.9±10.0 42.1±7.4 
Mean disease duration, 
years±SD 
NA 23.6±14.3 23.9±14.7 23.6±14.3 
Median EDSS (range) NA 2.5 (0-6.5) 2.5 (0-4) 
3 (2.5-
6.5) 
Table 5. Population characteristics. RR=relapsing-remitting; PP=primary 
progressive; OCB=oligoclonal Bands 
Italian patients were enrolled at the Multiple Sclerosis Centre of the Cà 
Granda Foundation, Scientific Institute for Hospitalisation and Care, 
Ospedale Maggiore General University Hospital of Milan, while Belgian 
patients came from the University Hospitals of Leuven. The control group 
consisted of healthy volunteers matched by ethnic background and age. 
The Italian exploratory population consisted of 5 subjects affected by 
relapse-remitting (RR) MS, 5 with the primary progressive form and 6 
controls.   
The Italian validation cohort included 28 RR-MS patients, 8 progressives, 2 
patients with an undefined diagnosis and 25 controls. 
The Belgian replication group was formed by 17 RR-MS, 7 PP-MS and 23 
controls [table 5]. 
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All patients were submitted to the standard procedure for MS and signed the 
informed consent. In particular, medical history, physical and neurological 
examination, screening laboratory tests and brain Magnetic Resonance 
Imaging were performed. Diagnoses were based on current consensus 
criteria [62]. 
14 mL of blood were sampled in 
BD Vacutainer® CPT™ 
Mononuclear Cell Preparation 
Tube for each case and control. 
When the sample reached room 
temperature, it was centrifuged 
at 1,500 G for 15 minutes. After 
centrifugation, mononuclear 
cells and platelets appeared in a 
whitish layer just under the 
plasma layer [Figure 23]. The 
plasma was removed, the cell 
layer was collected in a tube and the cells were washed twice with PBS 1% 
and centrifuged at 680 G for 8 minutes. 
Then, we aspirated as much supernatant as possible without disturbing the 
cell pellet, and resuspended cell pellet in 1 mL of Trizol reagent. 
The samples were stored at -80°C. 
 
3.1.2 RNA isolation and purification from peripheral blood 
mononuclear cells (PBMC). 
We used the following protocol to extract RNA from PBMC: 
Figure 23 BD Vacutainer® CPT™ 
Mononuclear Cell Preparation Tube. 
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a) transfer 1 mL of sample to a new Eppendorf; add 0.2 mL of 
chloroform per 1 mL of Trizol reagent; 
b) vortex samples vigorously for 15 seconds and incubate them in ice 
for 5 minutes; 
c) centrifuge at 15,000 G for 25 minutes at 4°C; following 
centrifugation, the mixture separates into a lower red, phenol-
chloroform phase, an interphase, and a colourless upper aqueous 
phase; 
d) transfer the aqueous phase into a new Eppendorf and precipitate 
the RNA by mixing with isopropanol; use the same amount of the 
aqueous phase; 
e) place 2 µL of glycogen in the Eppendorf cup and incubate overnight 
at -30°C; 
f) the next day, vortex the sample and centrifuge it at 15,000 G for 15 
minutes at 4°C; 
g) remove the supernatant and add 500 µL of ethanol; 
h) vortex the sample and centrifuge it at 15,000 G for 15 minutes at 
4°C; 
i) remove the supernatant and air dry the RNA pellet for 20 minutes; 
j) add 22 µL of RNAse-free water and quantify the amount of RNA and 
purity by using the NanodropTM Lite Spectrophotometer (Thermo 
Fisher Scientific); RNA purity was measured by optical density and 
only samples with an OD 260/280 ratio ranging from 1.8 to 2 and an 
OD 260/230 of 1.8 or greater were used. 
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3.1.3 Retrotrascription in cDNA, pre-amplification and genic 
expression analysis. 
Exploratory analysis. 
LncRNAs were retro-transcripted using a cDNA Synthesis First Strand kit 
(Qiagen) for use with SYBR green technology arrays, following the 
procedure described below: 
a) briefly (10-15 seconds) spin down all reagents; 
b) prepare the genomic DNA elimination mix for each RNA sample, 
according to Table 6. 
Component Amount 
RNA 25 ng – 5 µg 
Buffer GE 2 µl 
Nuclease-free water variable 
Total volume 10 µL 
Table 6. DNA elimination mix 
c) incubate the genomic DNA elimination mix at 42°C for 5 minutes, 
then immediately place on ice for at least 1 minute; 
d) prepare the reverse-transcription mix according to Table 7: 
 
Component Amount 
5x Buffer BC3 4 µL 
Control P2 1 µL 
R3 Reverse Transcriptase mix 2 µL 
Nuclease-free water 3 µL 
Total volume 10 µL 
Table 7. Reverse-transcription mix 
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e) add 10 µL of the reverse-transcription mix to each tube containing 
10 µL of the DNA elimination mix; blend gently by pipetting up and 
down; 
f) incubate at 37°C for 60 minutes; then, immediately stop the reaction 
by incubating at 95°C for 5 minutes; 
g) add 91 µL of nuclease-free water. Store at -20°C. 
 
cDNA was pre-amplified using the commercial kit RT2 lncRNA PreAMP 
cDNA synthesis (Qiagen) in association with a specific primer mix RT2 
lncRNA PreAMP Primer Mix for Human lncFinder (Qiagen): 
a) thaw the RT2 PreAMP PCR Mastermix and the RT2 lncRNA PreAMP 
Primer Mix at room temperature; 
b) prepare the pre-amplification mix according to Table 8; 
 
Component Amount 
RT2 PreAMP PCR Mastermix 12.5 µL 
RT2 lncRNA PreAMP Primer Mix 7.5 µL 
Total volume 20 µL 
Table 8. Pre-amplification mix 
                  
c) pipet 5 µL of cDNA into a PCR tube and add 20 µL of pre amplification 
mix; 
d) mix gently by pipetting up and down; spin briefly to remove any air 
bubbles and collect all the liquid at the bottom of the tube; 
e) place the tubes in the real-time cycler and start the programme 
according to the following cycling conditions:  
1 cycle 95°C for 10 min. 
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12 cycles 95°C for 15 sec. 
                60°C for 2 min.  
Hold at 4°C. 
lncRNAs expression levels were evaluated by human LncProfiler qPCR array 
(SBI), a panel of long non-coding RNAs related by pathway or disease, in 
SYBR green Technology using StepOnePlus Real time PCR System 
(Applied BioSystems) [Figure 24]. 
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Figure 24. Human LncProfiler qPCR array (SBI) 
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a) dilute 10 µL of cDNA in 90 µL of water; 
b) prepare the RT-PCR mix according to Table 9; 
 
Component Amount 
2x RT2 SYBRgreen PCR Mastermix 1275 µL 
Nuclease-free water  1175 µL 
cDNA 100 µL 
Total volume 25 µL/well 
Table 9. RT-PCR mix 
c) in a plate place 25 µL of RT-PCR mix in each well and start the 
programme according to the following cycling conditions: 
1 cycle 95°C for 10 min. 
40 cycles 95°C for 15 sec. 
                60°C for 30 sec. 
Hold at 4°C. 
 
Validation analysis 
lncRNAs were retro-transcribed using SuperScript III Reverse 
Transcriptase (LifeTechnologies). 
a) Prepare the mix according to Table 10; 
 
Component Amount 
RNA 5 ng tot max 
Oligo(dT) 50µMol 1 µL 
Annealing buffer 1 µL 
Total volume variable 
Table 10. SuperScript III Reverse Transcriptase mix. 
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b) incubate the mix at 56°C for 5 minutes, then immediately place on ice 
for at least 1 minute; 
c) add 10µL of 2X First-Strand Reaction Mix and 2 µL of SuperScript III/ 
RNAase OUT Enzime Mix to each sample; 
h)  incubate at 50°C for 50 minutes. Then immediately stop the 
reaction by incubating at 85°C for 5 minutes. Store at -20°C. 
Customised plates with TaqMan probes were drawn for best hits and lncRNA 
expression levels were measured in RT-PCR with the StepOnePlus Real 
time PCR System (Applied BioSystems). Two housekeeping genes, 18S and 
GAPDH, provided normalisation [Table 11]. 
lncRNA Assay ID lncRNA Assay ID 
HOTAIR Hs003296680_s1 TUG1 Hs00215501_m1 
HULC Hs01909631_s1 XIST Hs02758991_g1 
ANRIL Hs04259476_m1 AIR Hs04332496_m1 
GOMAFU Hs00402814_m1 Sox2ot Hs00415716_m1 
H19 Hs00262142_g1 BACE1-AS Hs04232267_s1 
MALAT1 Hs00273907_s1 Housekeeping 
gene 
Assay ID 
MEG9 Hs01593046_s1 GAPDH Hs02758991_g1 
Nespas Hs00294858_m1 18S Hs19999999_m1 
NRON Hs04274940_s1   
Table 11. lncRNA Taqman probes 
 
a) Prepare the RT-PCR mix according to Table 12; 
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Component Amount 
Taqman Universal PCR Mastermix 5 µL 
Probe  0.5 µL 
cDNA 1 µL 
Nuclease free water 3.5 µL 
Total volume 10 µL/well 
Table 12. RT-PCR mix 
b) In a plate, place 10 µL of RT-PCR mix in each well and start the 
programme according to the following cycling conditions: 
1 cycle 95°C for 10 min. 
40 cycles 95°C for 15 sec. 
                60°C for 30 sec. Hold at 4°C. 
Replication analysis. 
lncRNA were retro-transcribed using Multiscribe Reverse Transcriptase 
(Thermo Fisher Scientific).  
a) Prepare the mix according to Table 13. 
Component Amount 
10X RT Buffer 2 µL 
25X dNTPs Mix(100 mM) 0.8 µL 
10X RT random primers 2 µL 
Multiscribe reverse transcriptase 1 µL 
RNase inhibitor 1 µL 
Nuclease-free Water 3.2 µL 
RNA 10 µL 
Total volume 20 µL 
Table 13. Multiscribe Reverse Transcriptase mix. 
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b) Place in the thermal cycler at these conditions: 
1 cycle 25°C for 10 min. 
1 cycle 37°C for 120 min. 
1 cycle 85°C for 5 sec. 
Hold at 4°C. 
 
lncRNA expression levels were measured by droplet digital PCR (QX200 
ddPCR BioRad), using Taqman Probes [Table 14]. 
 
lncRNA Assay ID Housekeeping 
gene 
Assay ID 
NRON Hs04274940_s1 GAPDH Hs02758991_g1 
TUG1 Hs00215501_m1   
GOMAFU Hs00402814_m1   
Table 14. Taqman probes for replication analysis. 
 
a) Prepare the ddPCR mix according to Table 15. 
Component Amount 
ddPCR SuperMix 11.5 µL 
Taqman probes 1.15 µL 
Nuclease-free water 7.85 µL 
Total volume 20.5 µL 
Table 15. ddPCR mix 
b) In a plate, in each well, place 20.50 µL of ddPCR mix and 2.5 µL of 
cDNA.  
c) Spin briefly to remove any air bubbles. 
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d) After loading a 20 µL ddPCR reaction, load 70 µL of droplet 
generating oil in the bottom wells of the DG8 cartridge [Figure 25]. 
 
 
Figure 25. DG8 cartridge 
e) Attach a gasket across the top of the DG8 cartridge and place it in 
the QX200 droplet generator, which produces about 20,000 droplets 
per sample.  
f) Droplets should be transferred to a 96-well plate by pipetting gently. 
g) After heat sealing, place the PCR plate in a thermal cycler for PCR 
using the following protocol:  
1 cycle: 95°C for 10 min. 
1 cycle: 95°C for 30 min. 
70 cycles:  56°C for 1 min (annealing) 
                  98°C for 10 min. 
Hold at 12°C. 
h) Following PCR amplification of the target in the droplets, place the 
ddPCR plate in a QX200 droplet reader. The droplet reader and the 
QuantaSoft software count the PCR-positive and the PCR-negative 
droplets to provide absolute quantification of the target. 
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3.1.4 Statistical analysis.  
 
To analyse data from human LncProfiler qPCR arrays (SBI), we used a 
software based on the ΔΔCt method and provided for the normalisation of 
five housekeeping genes. The P-values of expression data obtained from 
cases and controls were calculated using Student's t test values of 2(- ΔCt).  
For validation analysis-related quantification (RQ) of lncRNA, expression 
levels of cases were compared with that of controls using GraphPad Prism 6 
scientific software and R. 
 
Regarding ddPCR data, Poisson statistical analysis of the numbers of 
positive and negative droplets yielding absolute quantitation of the target 
sequence was performed by QuantaSoft software (BioRad). R was used to 
compare cases and controls and disease forms. 
3.2 Long non-coding expression profile in exosomes isolated from 
serum of multiple sclerosis patients 
3.2.1 Population and sample collation  
6 mL of blood were sampled in BD Vacutainer® Blood CollectionTube 
(without anticoagulant) for each case and control. When the sample reached 
room temperature, it was centrifuged at 1,500 G for 10 minutes. 500 µL of 
serum were aliquoted in cryovials and stored at -80°C. 
An MS patient cohort was recruited and the characteristics are summarised 
in Table 16.  
 
97 
 
 Controls MS-all RR-MS PP-MS 
N 10 17 10 7 
Gender (M:F) 5:5 4:13 3:7 1:6 
Mean age, years±SD 46±14.66 40±15.87 36±9.80 54±14.65 
Mean age at onset, 
years±SD 
NA 52±6.06 33±11.08 50±15.25 
Mean disease duration, 
years±SD 
NA 4±3.78 3±4.26 5±3.02 
Median EDSS (range) NA 2 (1-4.5) 2 (1-3.5) 2 (2-4.5) 
Table 16. Population characteristics for exosomal analysis. RR=relapsing-remitting; 
PP=primary progressive; OCB=oligoclonal Bands 
 
3.2.2 Exosome purification and characterisation  
Exosome isolation 
The Exo-FlowTM Exosome Purification kit (SIB) was used to isolate 
exosomes from serum. We followed the manufacturer’s protocol: 
1. Place 500 µL of serum in a new Eppendorf and centrifuge for 25 min. 
at 3,000 G; 
2. transfer the supernatant into a new Eppendorf and add 125 µL of 
ExoQuick precipitation reagent;  
3. mix by inversion and place at 4°C for 1 hour and 30 minutes; 
4. centrifuge at 1,500G for 30 min. at 4°C; 
5. remove the supernatant and repeat centrifugation for 5 minutes; 
6. remove all supernatant and resuspend the exosome pellet in 500 µL 
of PBS 1%; 
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7. Store at -80°C. 
Exo-Flow FACS magnetic bead preparation 
1. Briefly vortex bead slurry and then pipette 40 µL of it into each 
Eppendorf. 
2. Place the samples on a magnetic stand for 5 minutes. 
3. Carefully remove the supernatant. Make sure not to disturb the 
magnetic beads. 
4. Remove samples from the magnetic stand and add 500 µL of Bead 
Wash buffer. Invert a few times. 
5. Place samples on a magnetic stand and repeat steps 2-4 for 2 
washes. 
6. Remove all liquid so only beads are on the side of the tube. 
Binding capture antibody to beads 
7. Remove tubes from the magnetic stand and add 10 µL of biotinylated 
capture antibody (Anti-CD171 (L1CAM), Abcam ab24345 1:5; Anti-
CD81, Abcam ab109201, Anti-TSG101, Abcam ab125011; AntiCD63, 
Abcam ab125011) per sample. Mix by pipetting up and down. 
8. Place tubes in ice for 2 hours. Flick the tube every 30 minutes to gently 
mix. 
9. Add 200 µL Bead Wash buffer and flick to mix. 
10. Place samples on the magnetic stand for 5 minutes. 
11. Carefully remove the supernatant. Make sure not to disturb the 
magnetic beads. 
12. Remove samples from the magnetic stand and add 500 µL of Bead 
Wash buffer. Invert a few times. 
13. Place samples on the magnetic stand and repeat steps 10-12 for 3 
washes. 
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14. Suspend capture antibody beads in 400 µL of Bead Wash buffer. 
Exosome capture 
15. Add 100 µL of concentrated, isolated exosomes to each bead sample 
for a total volume of 500 µL. 
16. Incubate overnight on a rotating rack at 4°C for capture. 
17. Place samples on a magnetic stand for 5 minutes. 
18. Carefully remove the supernatant. Make sure not to disturb the 
magnetic beads. 
19. Remove samples from the magnetic stand and add 500 µL of Bead 
Wash buffer. Invert a few times. 
20. Place samples on a magnetic stand and repeat steps 3-5 for 2 
washes. 
Exosome staining 
21. Add 240 µL of Exosome Stain Buffer and 10 µL of Exo-FITC exosome 
stain to reach a final volume of 250 µL per sample. 
22. Place tubes on ice for 2 hours. Flick the tube every 30 minutes to 
gently mix. 
23. Place samples on the magnetic stand for 5 minutes. 
24. Carefully remove the supernatant. Make sure not to disturb the 
magnetic beads. 
25. Remove samples from the magnetic stand and add 500 µL of Bead 
Wash buffer. Invert a few times. 
26. Place samples on the magnetic stand and repeat steps 23-25 for 3 
washes. 
27. Resuspend samples in 300 µL of Bead Wash Buffer for flow 
cytometry. 
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Exosome elution 
28. Place the stained exosomes/bead complexes on the magnetic stand 
for 5 minutes. 
29. Remove samples from the magnetic stand and remove buffer. 
30. Add 300 µL Exosome Elution Buffer. Invert a few times. 
31. Incubate on a rotating rack at 25°C for 40 minutes. 
32. Place samples on the magnetic stand for 5 minutes. 
33. Carefully remove the supernatant containing your eluted exosomes 
and transfer to a fresh tube. 
Fluorescence Activated cell sorting (FACS) analysis  
The antibody-bead complexes were sorted by FACS. We selected the 
exosomes of neural origin by using the antibody anti-CD171, also known as 
L1CAM (L1 cell adhesion molecule), diluted 1:5 in 1% PBS (initial 
concentration 500 ng/µL). 
Transmission electron microscopy for exosome 
characterisation 
We performed negative staining to improve contrast and easily differentiate 
edges and features of the sample: 
1) place 10 µL of sample on the grid covered by Forward (200 mesh); 
2) leave at room temperature for 10 minutes; 
3) dry the grids, placing them laterally on the filter paper; 
4) place the grids on a drop of saturated uranium acetate (dissolved in 
water) for 5-10 minutes; 
5) analyse the grid using TEM Leo912ab 80 kw. 
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Western Blot 
We performed Western Blot analysis according to standard protocols. Briefly, 
exosomes were dissolved in PBS with LDS Sample Buffer (Life 
Technologies®) and separated using 4-12% Bolt® Bis-Tris Precast Gels (Life 
Technologies®) with MOPS SDS running buffer (Thermo-Fisher Scientific®). 
Then samples were electro-transferred to PVDF membranes (Thermo-Fisher 
Scientific®) for 2 hours at 60V at room temperature, and the membranes were 
immunoblotted with primary antibodies overnight and then incubated with 
horseradish peroxidase-conjugated secondary antibodies (Pierce®,Thermo-
Fisher Scientific) for 1 hour. Immuno-positive bands were detected by 
enhanced chemiluminescence (Pierce®, Thermo-Fisher Scientific) according 
to the manufacturer’s instructions. The primary antibodies anti-L1CAM, anti-
TSG101 and anti-VPS35 came from Abcam®, anti-CD9 was purchased from 
Santa Cruz Biotecnology®. 
 
3.2.3 Long non-coding RNA isolation from exosomes 
LncRNA extraction 
lncRNA were isolated from exosomes using Total Exosome RNA and protein 
isolation (Ambion). 
1) Transfer 300 µL of isolated exosomes to a new Eppendorf (if the 
volume is less than 300 µL, bring to volume with 1% PBS). 
2) Under the hood, add 300 µL of Denaturing solution 2x and leave on 
ice for 5 minutes. 
3) Add 600 mL of chloroform. 
4) Vortex and centrifuge for 30 minutes at maximum speed at 4°C. 
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5) Carefully remove the aqueous (upper) phase without disturbing the 
lower phase or the interphase, and transfer it to a fresh tube. Note 
the volume obtained.  
6) Add 1.25 volumes of 100% ethanol to the aqueous phase, and mix 
thoroughly. 
7) Pipet 700 μL of the lysate/ethanol mixture onto the Filter Cartridge 
and centrifuge at 10,000 rpm for 2 minutes.  
8) Discard the flow-through, and repeat until all the lysate/ethanol 
mixture has passed through the filter.  
9) Pipet 700 µL of Wash Solution 1 on the filter. 
10) Centrifuge for 2 minutes at 10,000 rpm. 
11)  Place the collection tube filter in a new Eppendorf and add 500 µL of 
Wash Solution 2/3 directly on the filter. 
12)  Centrifuge for 2 minutes at 10,000 rpm. 
13)  Add 500 µL of Wash Solution 2/3 and repeat centrifugation. 
14)  Remove the eluted liquid and repeat centrifugation. 
15)  Place the collection tube filter in a new Eppendorf and add 30 µL of 
Elution Solution (preheated at 90°C) directly on the filter. 
16)  Centrifuge for 2 minutes at 10,000 rpm. 
17)  Store at -80°C.  
Qualitative and quantitative analysis of lncRNA. 
LncRNA were analysed using Agilent 2100 Bioanalyzer and RNA 6000 Nano 
(Agilent) kit.  
Using automated electrophoresis, the Agilent 2100 Bioanalyzer system 
provides sizing, quantitation, and purity assessments for RNA. 
Depending on the amount of RNA, it uses different chips, precisely the NANO 
chip, the PICO chip or, for RNA≤200nt the Small chip.  
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For NANO and PICO chip, RNA quality is indicated by the RNA integrity 
number (RIN), a tool designed to estimate the integrity of total RNA samples. 
Using this tool, sample integrity is no longer determined by the ratio of the 
ribosomal bands alone, but by the entire electrophoretic plot of the RNA 
sample, including the presence or absence of degradation products. 
Interpretation of an electropherogram is thus facilitated, comparison of 
samples is enabled and repeatability of experiments is ensured. 
The absolute value of RIN ranges between 0 and 10, where 0 represents 
completely degraded RNA, while 10 is the best quality RNA.  
The protocol is described below: 
 
1) bring the RNA 6000 Nano (Agilent) kit to room temperature;  
2) spin the RNA ladder and place it in a new Eppendorf; 
3) denature the RNA ladder at 70°C for 2 minutes and place it 
immediately on ice; 
4) place the RNA ladder in the RNase-free Eppendorf and store at -
70°C; 
5) denature 5 µL of RNA sample at 70°C for 2 minutes and immediately 
place it on ice; 
6) prepare the gel:  
- pipette 550 µL of RNA gel Matrix on the filter; 
- centrifuge at 1,500 G for 10 minutes at room temperature; 
- place 65 µL of filtered gel in a new Eppendorf; 
- store at 4°C for at least 4 weeks; 
7) vortex the RNA dye concentrate for 10 sec. and spin; 
8) pipette 1 µL on the filtered gel and vortex; 
9) centrifuge for 10 min. at 13,000 G at room temperature; 
10) Allow the gel-dye mix to balance at room temperature for 30 minutes 
before use, and protect  the gel- dye mix from light during this time; 
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11) take a new RNA Nano chip out of its sealed bag; 
12) place the chip on the chip priming station; 
13) pipette 9.0 μL of the gel-dye mix at the bottom of the well indicated 
with a “G” and dispense the gel-dye mix; 
14) set the timer to 30 seconds, ensuring that the plunger is positioned at 
1 mL, and then close the chip priming station; the lock of the latch will 
click when the Priming Station is correctly closed; 
15) press the plunger of the syringe down until it is held by the clip; 
16) wait for exactly 30 seconds and then release the plunger with the clip 
release mechanism; 
17) visually check that the plunger moves back at least to the 0.3 mL 
mark; 
18) wait for 5 seconds, then slowly pull back the plunger to the 1 mL 
position; 
19) open the chip priming station; 
20) pipette 9.0 μL of the gel-dye mix in each of the marked wells; 
21) load the marker: pipette 5 μL of the RNA 6000 Nano marker (diluted 
1:2) into the well marked with the ladder symbol and each of the 12 
sample wells [Figure 26A]; 
22) load the ladder and the samples: 
- pipette 1 μL of the RNA ladder into the well marked with the 
ladder symbol [Fig 26B]; 
- pipette 1 µL of RNase-free sample in the first well; 
- pipette 1 μL of each sample into each of the 12 sample wells 
[Fig 26C]; 
23) vortex using the IKA vortexer for 1 minute; 
24) run the Agilent 2100 Bioanalyzer [Figure 26]. 
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Retrotranscription, pre-amplification and lncRNA expression 
analysis by RT-PCR 
In order to obtain cDNA from lncRNA, RT2 preAMP cDNA synthesis kit 
(Qiagen): 
a) prepare the genomic DNA elimination mix for each RNA sample, 
according to Table 17; 
Component Amount 
RNA 8 µL 
Buffer GE 2 µL 
Total volume 10 µL 
Table 17. DNA elimination mix 
b) incubate the genomic DNA elimination mix at 42°C for 5 minutes, 
then immediately place on ice for at least 1 minute; 
c) prepare the reverse-transcription mix according to Table 18; 
 
 
 
Figure 26. Loading on chip. 
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Component Amount 
5x Buffer BC3 4 µL 
Control P2 1 µL 
cDNA Synthesis Enzyme mix 1 µL 
RNase Inhibitor 1 µL 
Nuclease-free water 3 µL 
Total volume 10 µL 
Table 18. Reverse-transcription mix 
d) incubate the reverse-transcription mix at 37°C for 60 minutes, then 
at 95°C for 5 minutes. Store at -20°C. 
cDNA was pre-amplified using the commercial kit RT2 lncRNA PreAMP 
cDNA synthesis (Qiagen) as previously described on page 78. 
After step e) add 2 µL of Side Reaction Reducer and incubate at 37°C for 15 
minutes, and then at 95°C for 5 minutes. Add 84 µL Nuclease-free water and 
store at -20°C. Gene expression levels of lncRNA derived from neural 
exosomes were evaluated using RT2 lncRNA PCR arrays LAHS-004ZC 
Figure 27 . Human LncFinder RT2 LncRNA array (QIAGEN) 
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(Qiagen) [Figure 27] and Human Inflammatory response and autoimmunity 
RT2 lncRNA PCR arrays LAHS-004Z [Figure 28] .  
These arrays contain 5 housekeeping genes (ACTB, B2H, RPLP0, RN7SK, 
SNORA73A), a control for genomic DNA contamination (HGDC), 3 wells for 
retrotranscription quality (RTC) and 3 positive controls (PPC). 
a) Prepare the RT-PCR mix according to Table 19. 
 
Component Amount 
2x RT2 SYBRgreen PCR Mastermix 1275 µL 
Nuclease free water  1173 µL 
cDNA 102 µL 
Total volume 25 µL/well 
Table 19. RT-PCR mix 
             
b) In a plate, place 25 µL of RT-PCR mix in each well and start the 
programme according to the following cycle conditions: 
1 cycle 50°C for 2 min. 
1 cycle 95°C for 10 min. 
40 cycles 95°C for 15 sec. 
Figure 28. Human Inflammatory response and autoimmunity RT2 LncRNA array (QIAGEN). 
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                60°C for 1 min.  
Hold at 4°C. 
 
Melting curve: 
95°C for 15 sec. 
60°C for 1 min. 
95°C for 30 sec. 
60°C for 15 sec. 
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4. RESULTS 
 
4.1 Long non-coding expression profile in peripheral blood 
mononuclear cells from multiple sclerosis patients.  
4.1.1 Exploratory analysis 
 
LncRNAs expression profiling performed by lncProfiler array showed a 
generalised dysregulation in MS patients, compared to controls [Figure 29 
A]. Some of this dysregulation presented different trends in RR-MS and PP-
MS [Figure 29 B-C]. In particular, a strong difference in 12 lncRNAs in MS 
patients, in comparison with controls, was observed. 
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Figure 29. LncRNA expression profile in A) total MS patients (n=10) vs controls (n=6), in B) 
RR-MS (n=5) vs controls and in C) PP-MS (n=5) and controls (n=5). Statistically significant 
lncRNAs dysregulation is marked with *. 
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4.1.2 Validation analysis 
Results were subsequently validated in an independent cohort [Table 5] and 
10 out of 12 lncRNAs were downregulated in MS, compared to controls 
[Figure 30; exact p-values in Appendix 1]. ANRIL [Figure 30 A], TUG1 [Figure 
29 K], XIST [Figure 30 L] (p<0.0001) and SOX2OT [Figure 30 I] (p<0.001) 
were strongly downregulated in RR-MS, while GOMAFU [Figure 30 D], 
HULC [Figure 30 E] (p<0.0001) and BACE-1AS [Figure 30 B] (p<0.001) 
showed a robust downregulation both in RR and Progressive MS, in 
comparison with controls.  
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Figure 30. Validation Analysis. LncRNA expression levels obtained by RT-PCR, in the 
Italian cohort, are relative and expressed as relative quantification (RQ). In the last 2 bars, MS 
patients are divided by disease form (RR-MS=relapsing remitting; PP-MS=primary 
progressive). GAPDH and 18S were used as normaliser genes. The median value of each 
group is indicated in red.  
Normality Test: Shapiro-Wilk’s test. *p<0.05; **p=0.01, ***p<0.001; ****p<0.0001 calculated 
by non-parametric Kruskall-Wallis test. Post-hoc test: Dunn’s test. 
 
ANRIL (p=0.024 r=0.976) and TUG1 (p=0.007 r=0.993) correlated with 
disability expressed by EDSS [Figure 31], whereas NRON with disease 
duration (R=0.949; p=0.05) [Figure 32]. 
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Figure 31. Correlation between lncRNAs expression levels and Expanded Disability 
Status Scale (EDSS) in the validation cohort. ANRIL (p=0.024 R=0.976) and TUG1 
(p=0.007 R=0.933) expression levels correlated with EDSS. Correlation was calculated by 
Spearman’s test. 
 
Figure 32. Correlation between NRON expression levels and disease duration (years) 
in the validation cohort. p=0.05 R=0.949. Correlation was calculated by Spearman’s test. 
 
4.1.3 Replication analysis 
After validation, we replicated NRON, TUG1 and GOMAFU in an 
independent Belgian cohort [Table 5], using another method, the ddPCR. We 
chose these lncRNAs because of their biologic implications with the disease. 
We confirmed that NRON and TUG1 [Figure 33, A and B, respectively] had 
lower levels in MS patients, compared with controls (p<0.05 and p<0.0001 
respectively). In particular, TUG1 was dysregulated both in RR-MS and PP-
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MS forms [Figure 33 B]. Conversely, the replication study failed for GOMAFU 
[Figure 33 C]. 
 
Figure 33. Replication analysis. LncRNA expression levels obtained by ddPCR, in the 
Belgian cohort, are relative and expressed as relative quantification (RQ). In the last 2 bars 
MS patients are divided by disease form (RR-MS=relapsing remitting; PP-MS=primary 
progressive). GAPDH and POLR2A were used as normaliser genes. The median value of 
each group is indicated in red.  
Normality Test: Shapiro-Wilk’s test. *p<0.05; **p<0.01, ****p<0.0001 calculated by non-
parametric Kruskall-Wallis test. Post-hoc test: Dunn’s test. 
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Correlations between the EDSS score and lncRNA expression levels failed 
to reach the significance threshold, although a trend toward a positive 
correlation between the NRON level and disease duration was found 
(p=0.048 r=0.471) [Figure 34]. 
 
Figure 34. Correlation between NRON expression levels and disease duration (years) 
in the replication cohort. p=0.048 R=0.471. Correlation was calculated with Spearman’s 
test. 
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4.2 Long non-coding expression profile in neural-derived exosomes 
from multiple sclerosis patients.  
4.2.1 Exosome purification and characterisation 
 
Neural-derived exosomes were isolated from serum of MS patients and 
healthy controls, and then submitted to microscopy, biochemistry and 
cytofluorimetric analysis. 
Microscopy analysis 
First, the presence of exosomes was evaluated, using the TEM. The global 
exosomes, marked by CD81, and specifically the neural-derived ones 
marked by L1CAM were present in our samples, and had the size and 
morphology typical of these vesicles, i.e., cup shape and spherical. [Figure 
35]. 
A)                                                  B) 
Second, we evaluated whether there are any differences in the morphology 
and/or integrity of exosomes extracted from frozen serum and those 
Figure 35. Exosomes extracted from serum. A) CD81 positive global exosomes. B) L1CAM 
positive neural-derived exosomes 
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extracted from fresh serum. As we can notice in figure 36, integrity did not 
change. Both fresh and frozen serum exosomes presented the intact 
phospholipid membrane, suggesting that the freezing process at -80°C does 
not affect their integrity. 
 
A)                                                    B) 
 
Freezing seems to stress the exosome membrane shape, which appears 
more jagged in frozen than in fresh vesicles [Figure 37]. However, this aspect 
does not affect exosomal integrity.  
 
Figure 36. Integrity of exosomes isolated from frozen  A) and fresh serum B). The 
exosomal vesicles are indicated by arrows. 
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A)                                                   B) 
 
 
 
 
 
 
Western blot analysis 
Western Blot analysis was performed to characterise and be sure that 
isolated vesicles were exosomes. 
CD9, TSG101, retromer (VPS35) protein and L1CAM expression was 
evaluated using specific antibodies in neural-erived exosome samples. All 
proteins analysed were detected [Figure 38]. 
Figure 37. Morphology of exosomes isolated from frozen A) and fresh serum B). 
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Figure 38. Western Blot analysis. A) VPS35 and TSG101. B) L1CAM (neural marker) and 
CD9 (general exosome marker) 
 
 
 
 
 
 
121 
 
Fluorescence-activated cell-sorting (FACS) analysis 
A complex bead-antibody that is able to recognise the L1CAM (or CD171), a 
specific membrane marker of neural-derived exosomes, was used. The 
exosomes were stained with fluorescein isothiocyanate (FITC), a 
fluorophore, which binds post-translational modifications that are 
physiologically present on the exosome surface. Once the bead-exosome 
bond was formed, a FACS analysis, using the cytofluorimeter, was 
performed [Figure 39]. 
Figure 39. FACS analysis. A; B) Negative control. C; D) Neural derived exosomes from 
serum of an MS patient. 
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The negative control was obtained by conjugation of the bead-antibody 
complex without exosomes. Its distribution diagram presents the energy 
absorbed by the bead-antibody conjugates (blue peak), in the absence of 
fluorescent emission FITC (green peak) [Figure 39 A]. Therefore, in the dot 
plot, the bead-antibody system is located in quadrant Q3 due to the absence 
of FITC fluorescence positivity [Figure 39 B]. Regarding the sample with 
exosomes, presenting the L1CAM marker and labelled in FITC, the 
distribution diagram shows an emission peak (green peak) [Figure 39 C], and 
in the respective dot plot we can notice a signal shift in quadrant Q4, where 
fluorescence is positive [Figure 39 D]. 
4.2.2 Exosomal RNA analysis by Bioanalyzer (Agilent) 
RNA analysis, in terms of amount, purity and non-coding RNA enrichment, 
was performed using Bioanalyzer (Agilent) [Figure 40; Appendix 1], and the 
samples were similar (mean±SD: 13.67±3.50 ng/μL). 
 
Figure 40. Exosomal RNA analysis 
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4.2.3 Long non-coding expression profiles 
 
Human LncFinder RT2 lncRNA array 
LncRNA expression profile performed by the Human LncFinder RT2 array 
showed generalised upregulation of lncRNA in 17 MS patients, compared to 
10 controls [Table 16, Figure 41]. Indeed, 49 lncRNA were upregulated, while 
9 were downregulated [Table 21].  
 
Figure 41. LncRNA expression profile MS vs CTRLS. A) Cluster diagram of fold change 
values for the 84 investigated lncRNAs. The data obtained are relative and expressed as fold 
change (fold difference), which is normalised lncRNA gene expression in the multiple sclerosis 
(MS) group divided by normalised lncRNA gene expression in the control group. Fold change 
values in MS patients versus controls. Each square represents a single lncRNA. Green 
squares represent lower than median level of lncRNA expression; black squares represent 
median level of lncRNA expression and red squares represent higher than median level of 
lncRNA expression. B) The scatter plot compares the normalised expression of every gene 
on the array between cases and controls by plotting them against one another to quickly 
visualise large gene expression changes. The central line indicates unchanged gene 
expression. 
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Table 20. Fold regulation of lncRNA. Upregulated lncRNA are indicated in red, while the 
downregulated lncRNA are blue. The comparison is cases vs controls. 
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Results from array analysis led to the identification of the 6 most significantly 
deregulated lncRNA (expressed as fold increase/decrease over controls): 
Antisense of IGF2R non-protein coding RNA (AIRN) (5.30-fold increase over 
controls, p=0.04); FAS antisense RNA 1 (FAS-AS1) (4.76-fold increase over 
controls, p=0.02); Hox transcript antisense RNA (HOTAIR) (4.47-fold 
increase over controls, p=0.03); Non-protein coding RNA, associated with 
MAP kinase pathway and growth arrest (NAMA) (13.24-fold increase over 
controls, p=0.01); Translation regulatory long non-coding RNA 1 (TRERNA1) 
(5.84-fold increase over controls, p=0.01) and HOXA cluster antisense RNA 
2 (HOXA-AS2) (0.56-fold increase over controls, p=0.04). 
Considering the data divided by disease form, we can notice different profiles 
between RR-MS and PP-MS, compared with controls [Figure 42]. 
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Figure 42. LncRNA expression profile. A) RR-MS vs CTRLS. C) PP-MS vs CTRLS A) and 
C) Cluster diagram of fold change values for the 84 investigated lncRNAs. The data obtained 
are relative and expressed as fold change (fold difference), which is the normalised lncRNA 
gene expression in the multiple sclerosis (MS) group divided by the normalised lncRNA gene 
expression in the control group. Fold change values in MS patients versus controls. Each 
square represents a single lncRNA. Green squares represent lower than median level of 
lncRNA expression; black squares represent median level of lncRNA expression and red 
squares represent higher than median level of lncRNA expression. A) RR-MS vs CTRLS; C) 
PP-MS vs CTRLS. B) and D) The scatter plot compares the normalised expression of every 
gene on the array between cases and controls by plotting them against one another to quickly 
visualise large gene expression changes. The central line indicates unchanged gene 
expression. 
 
RR-MS patients showed a general upregulation of lncRNA, compared to 
controls [Figure 42 A) and B); Table 22]. In particular, 5 lncRNA are 
significantly deregulated, precisely AIRN (10.77-fold increase over controls, 
p=0.04); DLX6 antisense RNA 1 (DLX6-AS1) (46.95-fold increase over 
controls, p=0.01); FAS-AS1 (11.37-fold increase over controls, p=0.001); 
HOTAIR (9.31-fold increase over controls; p=0.02); and TRERNA1 (6.61-fold 
increase over controls, p=0.003). 
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PP-MS patients showed a different profile [Figure 42 C) and D); Table 23], 
where only SOX-2OT have a significant upregulation (8.95-fold increase over 
controls, p=0.02).  
 
Table 21. Fold regulation of lncRNA in RR-MS patients compared with controls. 
Upregulated lncRNA are indicated in red, while the downregulated lncRNA are blue.  
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Table 22. Fold regulation of lncRNA in PP-MS patients compared with controls. 
Upregulated lncRNA are indicated in red, while the downregulated lncRNA are in blue.  
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Moreover, we performed a direct comparison between the subgroups RR-
MS and PP-MS [Figure 43; Table 23]. We found FAS-AS1 (4.87-fold increase 
over controls, p=0.015) and MRPL23 antisense RNA 1 (MRPL23-AS1) (2.68-
fold increase over controls, p=0.038) upregulated in RR-MS, in comparison 
with PP-MS.  
 
 
Figure 43. LncRNA expression profile RR-MS vs PP-MS. A) Cluster diagram of fold change 
values for the 84 investigated lncRNAs. The data obtained are relative and expressed as fold 
change (fold difference), which is the normalised lncRNA gene expression in the relapsing-
remitting multiple sclerosis (RR-MS) group divided by the normalised lncRNA gene expression 
in the progressive MS (PP-MS). Each square represents a single lncRNA. Green squares 
represent lower than median level of lncRNA expression; black squares represent median 
level of lncRNA expression and red squares represent higher than median level of lncRNA 
expression. B) The scatter plot compares the normalised expression of every gene on the 
array between cases and controls by plotting them against one another to quickly visualise 
large gene expression changes. The central line indicates unchanged gene expression. 
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Table 23. Fold regulation of lncRNA in RR-MS patients compared with PP-MS. 
Upregulated lncRNA are indicated in red, while the downregulated lncRNA are in blue. 
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Human Inflammatory response and autoimmunity array 
The LncRNA expression profile performed by the Human RT2 lncRNA 
Inflammatory Response & Autoimmunity array showed a general 
deregulation of lncRNA in MS patients, compared to controls [Figure 44]. We 
found 26 upregulated lncRNAs and 18 downregulated ones [Table 24]. 
 
Figure 44. LncRNA expression profile MS vs CTRLS. A) Cluster diagram of fold change 
values for the 84 investigated lncRNAs. The data obtained are relative and expressed as fold 
change (fold difference), which is the normalised lncRNA gene expression in the multiple 
sclerosis (MS) group divided by the normalised lncRNA gene expression in the control group. 
Fold change values in MS patients versus controls. Each square represents a single lncRNA. 
Green squares represent lower than median level of lncRNA expression; black squares 
represent median level of lncRNA expression and red squares represent higher than median 
level of lncRNA expression. B) The scatter plot compares the normalised expression of every 
gene on the array between cases and controls by plotting them against one another to quickly 
visualise large gene expression changes. The central line indicates unchanged gene 
expression. 
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Table 24. Fold regulation of lncRNA in MS patients compared with controls. 
Upregulated lncRNA are indicated in red, while the downregulated lncRNA are in blue. 
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In particular, MZF-AS1 (0.47-fold decrease over controls, p=0.03), CEP83 
antisense RNA 1 (CEP83-AS1) (0.15-fold decrease over controls, p=0.02), 
RP11-282O18.3 (0.27-fold decrease over controls, p=0.02), RP11-84C13.1 
(0.28-fold decrease over controls, p=0.04), Small nucleolar RNA host gene 
7 (SNHG7) (0.064-fold decrease over controls, p=0.04) and TP73 antisense 
RNA 1 (TP73-AS1) (0.48-fold decrease over controls, p=0.04) were 
significantly downregulated, while RP11-38P22.2 (19.5-fold increase over 
controls, p=0.04) was upregulated. 
Considering the disease subgroups, RR-MS patients showed a significant 
downregulation in RP11-363G2.4 (0.07-fold decrease over controls, 
p=0.008) and in TP73-AS1 (0.76-fold decrease over controls, p=0.02), while 
RP11-38P22.2 levels are upregulated (22.32-fold increase over controls, 
p=0.04) [Figure 45 A) B); Table 25]. We found a general downregulation in 
lncRNA expression analysed in PP-MS, in particular FGF14-IT1 (0.08-fold 
decrease over controls, p=0.007) and RP11-282O18.3 (0.14-fold decrease 
over controls, p=0.04) were significantly altered [Figure 45 C) D); Table 26]. 
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Figure 45. LncRNA expression profile. A) RR-MS vs CTRLS. C) PP-MS vs CTRLS A) and 
C) Cluster diagram of fold change values for the 84 investigated lncRNAs. The data obtained 
are relative and expressed as fold change (fold difference), which is the normalised lncRNA 
gene expression in the multiple sclerosis (MS) group divided by the normalised lncRNA gene 
expression in the control group. Fold change values in MS patients versus controls. Each 
square represents a single lncRNA. Green squares represent lower than median level of 
lncRNA expression; black squares represent median level of lncRNA expression and red 
squares represent higher than median level of lncRNA expression. A) RR-MS vs CTRLS; C) 
PP-MS vs CTRLS. B) and D) The scatter plot compares the normalised expression of every 
gene on the array between cases and controls by plotting them against one another to quickly 
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visualise large gene expression changes. The central line indicates unchanged gene 
expression. 
 
Table 25. Fold regulation of lncRNA in RR-MS patients compared with controls. 
Upregulated lncRNA are indicated in red, while downregulated lncRNA are in blue.  
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Table 26. Fold regulation of lncRNA in PP-MS patients, compared with controls. 
Upregulated lncRNA are indicated in red, while the downregulated lncRNA are in blue. 
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Comparison of the exosomal lncRNA profile between RR-MS and PP-MS 
groups did not reveal any significant differences [Figure 46, Table 27]. 
 
Figure 46. LncRNA expression profile RR-MS vs PP-MS. A) Cluster diagram of fold 
change values for the 84 investigated lncRNAs. The data obtained are relative and 
expressed as fold change (fold difference), which is the normalised lncRNA gene expression 
in the relapsing-remitting multiple sclerosis (RR-MS) group divided by the normalised 
lncRNA gene expression in the progressive MS (PP-MS). Each square represents a single 
lncRNA. Green squares represent lower than median level of lncRNA expression; black 
squares represent median level of lncRNA expression and red squares represent higher 
than median level of lncRNA expression. B) The scatter plot compares the normalised 
expression of every gene on the array between cases and controls by plotting them against 
one another to quickly visualise large gene expression changes. The central line indicates 
unchanged gene expression. 
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Table 27. Fold regulation of lncRNA in RR-MS patients, compared with PP-MS. 
Upregulated lncRNA are indicated in red, while downregulated lncRNA are in blue. 
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5. DISCUSSION  
 
Emerging evidence has revealed that lncRNAs play a pivotal role in the 
regulation of immunological functions and autoimmunity [135]. In order to 
highlight the role of these molecules in MS, we conducted an in-depth 
investigation of the cellular and exosomal lncRNA expression profile in 
different cohorts of MS patients using different methods.  
In order to reduce any potential confounding factors, blood withdrawal was 
performed early in the morning between 8.00 am and 10.00 am, and all 
patients were not under immunomodulating or anti-inflammatory therapies at 
the time of sampling.  
The results from cellular lncRNAs showed a general dysregulation of their 
expression levels in MS patients, compared to controls, in the exploratory 
analysis cohort, both considering the overall MS population, compared to 
controls, and when comparing lncRNA levels stratified according to the 
different MS forms. The further validation step performed in independent 
Italian MS and control populations confirmed the dysregulation observed in 
the initial exploratory step.  
Among the validated lncRNAs, we further focused on NRON, TUG1 and 
GOMAFU for the subsequent replication step in the Belgian cohort. These 
lncRNAs were chosen because of their possible implication in the 
pathogenesis of MS due to their involvement in inflammatory and 
neurodegenerative processes. NRON and TUG1 were replicated in the 
Belgian cohort, whereas GOMAFU did not pass the replication step, despite 
a trend toward downregulation of its expression level in patients. 
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NRON is an lncRNA repressor of the nuclear factor of activated T cells 
(NFAT), which interacts with members of the importin-beta superfamily and 
acts as specific regulator of NFAT nuclear trafficking [112]. NFATs regulate 
the transcriptional induction of genes encoding for immune 
modulators/activators, such as granulocyte-macrophage colony-stimulating 
factor (GM-CSF), gamma interferon (IFNγ), CD5, CD25, CD28, CD40, 
interleukin- (IL-) 2, IL-3, IL-4, IL-5, IL-13, IL-8 [185]. In T lymphocytes, NFAT 
proteins govern gene expression that regulates their development, 
activation, differentiation, as well as the induction and maintenance of T-cell 
tolerance. Furthermore, data from murine and cell line models highlight the 
role of NFAT/Ca2+ calmodulin pathway in CNS. In particular, it participates in 
signalling cascades that are pivotal for Schwann cell myelination [185]. Dietz 
et al. also demonstrated that NFAT1 and NFAT2 deficit attenuate EAE in 
animal models, underscoring the importance of this pathway in the 
pathogenesis of MS [186].   
NRON expression level in PBMC of MS patients was found to be lower in 
cases than in controls. Therefore, we investigated the expression level of its 
target gene NFAT, following the hypothesis of regulation of NFAT expression 
orchestrated by NRON. However, we did not find any significant differences 
in NFAT expression levels in the MS cases compared (data not shown) and 
no correlation was found with NRON expression levels. The NRON/NFAT 
pathway is a complex; hence, other alternative mechanisms could probably 
be involved in this regulation.  
TUG1 is expressed in the developing retina and brain, showing the highest 
levels in the cortex. It is involved in the regulation of cell cycle and apoptotic 
processes mediated by p53 [187]. Indeed, TUG1 expression is activated 
after DNA damage, and its promoter presents several p53 binding sites. 
141 
 
When it is associated with polycomb repressive complex 2 (PRC2), it acts as 
repressor for a number of cell cycle genes [109]. Moreover, in the context of 
the neurodegenerative disease, it was found to be deregulated in patients 
suffering from the trinucleotide repeat neurodegenerative condition [88]. 
A robust downregulation of TUG1 expression levels was observed in MS 
patients, compared to controls. Interestingly, by stratifying the results 
according to the disease form, the lowest expression levels were observed 
in the PP-MS. TUG1, shown to be involved in the apoptotic-p53 pathway, 
could play a key role in MS disease progression [188]. 
Despite these results, Santoro et al. showed an opposite trend of TUG1 
expression in serum from MS patients [91]. The reason could be the different 
biological source chosen for the analysis or a possible active role of TUG1 in 
intercellular communication. Its increased free circulating levels could 
originate from the release in the cellular milieu by exosomes, an enriched 
source of non-coding RNA. 
GOMAFU, alias MIAT, is predominantly expressed in the CNS [119], where 
it regulates the differentiation of neural stem cells into oligodendrocytes 
[117]. GOMAFU can bind the splicing factor 1 (SF1) protein through its 
UACUAAC repeat sequences. This sequence is a much stronger intron 
branch point sequence than found in most mammalian introns. Moreover, in 
vitro GOMAFU binding to SF1 can inhibit splicing and spliceosomal complex 
formation, suggesting that it can regulate splicing efficiency [114]. 
Dysregulation of GOMAFU leads to alternative splicing patterns that 
resemble those observed in schizophrenia for the archetypal schizophrenia-
associated genes DISC1 and ERBB4 [189]. 
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Although in the Italian cohort GOMAFU showed a strong downregulation in 
MS patients, compared to controls, including RR-MS and PP-MS forms, we 
did not replicate our results in the Belgian population. It could be due to the 
small number of patients, probably too low to explain the variability of the 
population.  
Moreover, it is interesting to notice that NRON correlates with the disease 
duration, while ANRIL and TUG1 positively correlate with the disability 
measured by EDSS. This last aspect can be due to the progression of 
neurodegeneration. The association of non-coding RNA levels with EDSS 
and disease duration has been previously reported [85,86]. This prompts not 
only a possible involvement of these molecules in MS mechanisms, but also 
an important role as biomarkers for MS progression.  
Regarding the study of lncRNA extracted from exosomes, we performed two 
parallel analyses using two different commercial arrays, Human LncFinder 
RT2 array and Human Inflammation response and autoimmunity array 
(QIAGEN). 
The analysis conducted with Human LncFinder RT2 array showed an overall 
upregulation of lncRNA in MS patients, in comparison with healthy controls. 
In particular, 7 lncRNA were significantly deregulated, and some of these 
could be linked with MS pathology. 
The antisense of the insulin-like growth factor 2 receptor (IGF2R) non-protein 
coding RNA (AIRN) overlaps the second intron of the insulin-like growth 
factor 2 receptor gene on the opposite strand. A CpG island associated with 
the second intron denotes an active promoter that drives the expression of 
this gene. The related mouse gene is responsible for silencing the IGF2R 
gene and flanking genes in the imprinted gene cluster of mice [190]. IGF2, 
143 
 
like the other insulin-like growth factors (IGFs), is a neurotrophic factor, and 
promotes survival and differentiation of neuronal cells. Its receptor, IGF2R, 
was studied in amyotrophic lateral sclerosis (SLA), where it showed 
upregulation in reactive astrocytes in the spinal cord of transgenic rats [191].  
IGF2R is expressed in murine T lymphocytes. In particular, Yang et al. 
observed IGF2R expression in more than 90% of murine and human Treg 
cells but in less than 10% of effector CD4+ T cells. The activation of this 
receptor induces Treg cell proliferation and the release of TGFβ, with a 
consequent immune suppressive effect [192].  
Geng et al. described the anti-inflammatory role of IGF2R also in B cells. 
They conducted a study in ovalbumin (OVA)-specific B cells and showed how 
IGF2 markedly enhanced the expression of IL-10 in these cells [193]. 
Moreover, a study about the presence of IGF2R in MS astrogliotic plaques 
revealed that this receptor is not present in them, excluding their involvement 
in astrogliosis [194]. 
 
In MS, Breg and Treg cell functions are altered [195], and microglia-mediated 
inflammation is a key point in the progression of the disease. We found that 
upregulation of AIRN was able to repress IGF2R, and this suggests that 
IGF2R expression could be downregulated in the target cells of neural 
exosomes. The immune cells could be the effector cells and their activity 
could consequently be deregulated, with a persistent inflammatory status. 
Indeed, it is interesting to note that our data underscored how AIRN is 
upregulated in the RR-MS form, which is typically characterised by a robust 
inflammation.  
A second lncRNA we found that significantly upregulated not only in all MS 
patients, but also in the subgroup of RR-MS, in comparison with controls, 
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was FAS antisense RNA 1 (FAS-AS1). Moreover it showed the same 
significant upregulation also in the RR-MS group, in comparison with PP-MS.  
FAS-AS1 might regulate the expression of alternative Fas splice forms 
through pre-mRNA processing [196]. A recent study showed that FAS-AS1 
is regulated by NF-κB, where decreasing NF-κB activity levels were tracked 
with increasing transcription of FAS-AS1 during human erythropoiesis [197].  
 
Fas and its ligand, FasL, are two molecules that belong to the TNF family, 
and are able to activate the caspase cascade and induce apoptosis in cells. 
Fas-FasL interaction is important in the regulation of immune homeostasis, 
and controls the tolerance mechanism. Indeed, it is required for the death of 
autoreactive T and B cells [198,199]. Moreover, the high expression of FasL 
in Th1 and its low expression in Th17 regulate the different cell death 
sensitivity of these immune cells [200]. In the MS contest, when FAS-AS1 is 
expressed in high levels, the expression of Fas can be downregulated and, 
finally, the autoreactive lymphocytes, Th1 and Th17 cells, can escape the 
programmed cell death and persist in inflamed sites.  
Fas-FasL could also play a protective role by regulating Treg cells. These 
immune cells express low levels of FasL, probably because their prolonged 
survival is important to dampen the immune reaction. 
Fas-FasL is important in immune privileged brain tissue. The expression of 
FasL by BBB cells favours an immune-suppressive environment in the CNS 
[200]. Therefore, FAS-AS1-mediated alteration of these processes might 
reduce the inflammatory processes.  
In the CNS, MS patients present an increase in Fas, depending on 
exogenous IL-22. Then, Fas increases phosphorylation of mitogen- and 
stress-activated protein kinase 1 and activates the nuclear factor-κB pathway 
in oligodendrocytes, leading to an increase in Fas and oligodendrocyte 
apoptosis [201]. Since Fas-FasL interaction is also present in neurons and 
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in oligodendrocytes, they can be other possible target cells of exosomes. In 
this case, FAS-AS1 could reduce their death, reducing Fas levels. 
HOX transcript antisense RNA (HOTAIR) showed an upregulation both in 
MS and RR-MS patients, in comparison with controls. HOTAIR is located 
within the Homeobox C (HOXC) gene cluster on chromosome 12 and is co-
expressed with HOXC genes. It functions through an RNA product, which 
binds lysine-specific demethylase 1 (LSD1) and Polycomb repressive 
complex 2 (PRC2), and acts as a scaffold to assemble these regulators at 
the HOXD gene cluster, thereby promoting epigenetic repression of HOXD. 
To date several studies have underscored its role in tumours, such as glioma, 
but not in autoimmune diseases. Therefore, further analyses are required to 
clarify the involvement of HOTAIR in MS. HOXA cluster antisense RNA 2 
(HOXA-AS2) was downregulated in MS patients, in comparison with controls. 
HOXA-AS2 is located between the HOXA3 and HOXA4 genes in the HOXA 
cluster. These genes are expressed in human CD34+ T cells [202] and are 
involved in erythropoiesis and in cancer. Moreover, a number of genes of the 
HOXA, HOXB, and HOXC appear to play a role in lymphoid cells. A recent 
study showed that HOXA-AS2 is an apoptosis repressor in all trans retinoic 
acid-treated NB4 promyelocytic leukaemia cells [203], but no data about its 
connection with autoimmune diseases are reported in the literature.  
Likewise, data are scarce on the non-protein coding RNA associated with the 
MAP kinase pathway and growth arrest (NAMA), which is upregulated in 
cases and not in controls in our study. It seems involved in thyroid carcinoma 
[204,205], but it has not been studied in detail so far.  
The translation regulatory long non-coding RNA 1 (TRERNA1), which is 
upregulated in the MS group, was studied in cancer. Indeed, it is involved in 
metastasis promotion and in invasion by regulating various pro-invasive 
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proteins. It acts as an enhancer and is able to regulate the expression of 
SNAI1, its neighbour gene [206]. No data about its link with autoimmunity or 
neurodegeneration has been published in Literature. 
In RR-MS patients AIRN, FAS-AS1, HOTAIR, OIP5-AS1 and TRERNA 
showed the same deregulation as the total MS group. Only one lncRNA 
presented a different expression, the DLX6 antisense RNA 1 (DLX6-AS1). 
Up to now, it has been studied in cancer [207] but there is no significant 
report about the relationship between lncRNA DLX6-AS1 and MS. Its target 
gene DLX6 encodes a member of a homeobox transcription factor gene 
family. This family comprises at least 6 different members that encode 
proteins with roles in forebrain and craniofacial development. Mutations in 
DLX6 have been described in autism [208].  
Instead, Sox 2 overlapping transcript (SOX2-OT) was significantly up-
regulated in the PP-MS group. SOX2OT is highly expressed in brain and is 
located in chr3q26.33, which is frequently amplified in cancer tissue [209]. 
Little is known about its exact role. Recent studies have described it as a 
transcription regulator. Similar to SOX2, SOX2-OT is highly expressed in 
embryonic stem cells and downregulated upon the induction of 
differentiation. Indeed, SOX2-OT is involved in neurogenesis [96,210,211]. 
New data are required to better understand its role in MS.  
The analysis conducted using Human LncRNA RT2 Inflammation response 
and Autoimmunity array showed an overall downregulation of lncRNA in MS 
patients, in comparison with healthy controls.  
Myeloid Zinc Finger 1 antisense RNA1 (MZF1-AS1) is the regulator of MZF1, 
a SCAN-Zinc Finger (SCAN-ZF) transcription factor family member, which 
has been studied for tumours [212]. MZF1 is physiologically involved in early 
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myeloid lineage differentiation and pro-inflammatory effector function, and 
pathologically in the aetiology of different solid cancer [212,213]. 
Interestingly, MZF1-AS1 is downregulated in MS patients. Consequently 
MZF1 should be upregulated, and this should compete to support the 
inflammatory processes. 
The target of CEP83-AS1 has been studied always in the field of cancer. 
CEP83 is a centriolar protein that is involved in primary cilium assembly. Not 
only is it involved in colorectal cancer [214], but also in infantile 
nephronophthisis and intellectual disability [215]. Our study underscored 
downregulation of CEP83-AS1 in the MS group, but its biological meaning in 
MS pathogenesis is not known. 
The RP11-282O18.3 gene encodes pre-mRNA processing factor 31 
(PRPF31), a component of the spliceosome complex. Defects in this gene 
lead to a state of generalised splicing dysfunction. PRPF31 has been 
associated with retinal dystrophy, a group of diseases characterised by 
degeneration of the retinal cells [216]. We observed its downregulation in the 
MS group and in the PP-MS subgroup. Considering PRPF31 involvement in 
the degeneration of photoreceptor cells, and since deregulation specifically 
occurs in the PP-MS group, we could theorise a possible role of this lncRNA 
in neurodegeneration. Further studies are needed to clarify this hypothesis. 
As RP11-282O18.3, FGF14 intronic transcript 1 (FGF14-IT1) was 
downregulated in the PP-MS subgroup, in comparison with controls. It is the 
neighbour of the fibroblast growth factor 14 (FGF14), and probably regulates 
its expression. FGF14 is expressed in the axon initial segments (AIS) of 
hippocampal pyramidal neuron structures. It is also located at the AIS in 
different types of cerebellar neurons. It is involved in the cortico-mesolimbic 
circuit, in particular in neurogenesis, plasticity and in synaptic transmission 
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[217,218]. Mutations in this gene have been associated with spinocerebellar 
ataxia 27 (SCA27), an autosomal-dominant disorder characterised by gait 
and movement disorders, nystagmus, and cognitive impairment [219,220]. 
FGF14 has also been associated with complex brain disorders as a result of 
its role in neurodegeneration processes [219]. It is interesting to note that we 
found FGF14-IT1 altered in the PP form. Indeed, inflammatory processes are 
in the background in this form of the disease, while neurodegeneration is 
evident. FGF14 expression is deregulated consequently to low levels of 
FGF14-IT1, and this situation could sustain the neurodegenerative 
mechanisms.     
Small nucleolar RNA host gene 7 (SNHG7) is downregulated in MS patients, 
in comparison with controls. SNHG7 has a role in the cellular response to 
radiation-induced oxidative stress [221]. In cancer, it has been reported as 
promoter of proliferation, migration and invasion, and apoptosis inhibitor 
[222]. To date, their functions in the autoimmune and neurodegenerative 
frameworks is unknown. 
Also TP73-AS1 presented downregulation in the MS group and in the RR-
MS subgroup, compared with controls. It is the antisense of the coding gene 
tumour protein p73 (TP73), which encodes a product that shares structural 
and functional characteristics with TP53 [223,224]. TP73-AS1 covers 
substantial portions of TP73, suggesting that TP73-AS1 may function by 
post-transcriptional regulation of TP73 gene expression [224]. TP73 encodes 
a transcription factor that belongs to the p53 family and is involved in cellular 
responses to stress and development. Many transcript variants resulting from 
alternative splicing and/or use of alternate promoters have been found for 
the TP73 gene, but the biological validity and nature of the full length of some 
variants have not been determined. 
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Wong et al. described TP73-AS1 downregulation in plasma cells from 
patients presenting multiple myeloma [225], but its involvement in MS 
disease needs to be investigated. 
lncRNA MALAT1 expression levels are downregulated both in PBMC and in 
neural-derived exosomes. Conversely, H19, HULC, MEG9, NRON, 
GOMAFU, TUG1 and XIST expression levels showed opposite directions, 
although there is no significant correlation between the deregulation of 
cellular lncRNA and neural-derived exosomal ones. This suggests that there 
are differences in the mechanisms that underpin the origin of these 
molecules. 
In PBMC, lncRNAs directly regulate gene expression. Dysregulation in their 
expression levels could primarily contribute to the disease. 
Instead, as cargo of neural-derived exosomes, lncRNA plays a different role. 
Indeed, they are involved in cell-to-cell communication between different 
target cells. Through endocytosis, they could incorporate lncRNA, which will 
adjust gene expression and cause an effector cell response. Therefore, the 
biological meaning of lncRNA levels altered by PBMC or neural-derived 
exosomes is different. However, the comprehensive investigation of both of 
them could elucidate the effective role of lncRNA in MS pathogenesis. 
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6. CONCLUSIONS  
 
Overall these data suggest that epigenetic regulation is carried out in a 
different way in pathogenic pathways that lead to a pro-inflammatory form 
rather than to a neurodegenerative one. 
This is the first large study about cellular and exosomal lncRNA in the MS 
framework. We analysed the expression profile of lncRNA derived from 
PBMC and neural exosomes. Regarding PBMC, we validated and replicated 
screening data in various populations, using different methods, and we 
identified 2 mainly deregulated lncRNAs, precisely NRON and TUG1.  
Then, we performed neuron-derived exosome extraction and studied their 
lncRNA content. These acquire remarkable importance in cell-to-cell 
communication and, as messenger, can support the pathogenic processes. 
We do not actually know what the target cell is, but neurons and immune 
cells are the most likely candidates. In this context, AIRN and FAS-AS1 have 
a biological significance that is linked with MS. The others have to be studied 
in depth to highlight their role in MS processes. The use of commercial arrays 
allowed to screen the main lncRNA known to be involved in the inflammatory 
response and in autoimmunity. A limit of these arrays is sensitivity in 
detecting small amounts of lncRNA. Indeed, all of our controls showed an 
“undetermined” measure of Ct for different lncRNAs, and we do not actually 
know if that molecule was not expressed or whether the method was unable 
to detect it. In the first case, some of the lncRNA analysed could be 
expressed only in the pathogenic context and not in the physiological one. In 
the second case, we need a more sensitive method. Therefore, these data 
should be validated and replicated in a larger population, using a different 
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method. In the future, it will be interesting to also study the lncRNA pattern 
in glial-derived exosomes. 
The aim of this study was to identify the possible lncRNA that is deregulated 
in MS, in order to find a good biomarker of disease progression to be used 
in a clinical setting. In this context, only after the molecules have been 
identified, and after seeing their clinical utility would we be interested in their 
biological functions and in their role in MS pathology. Thus, future studies 
are required to better clarify the role of deregulated lncRNA in MS. However, 
lncRNAs profiling could thus represent a new challenge in the search for 
easily detectable biomarkers of disease susceptibility and progression. 
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7. APPENDIX 1 
 
Exact p-values of validation and replication analysis 
lncRNA p- values Validation Analysis p-values 
Replication analysis  
MSvsCTRLS CTRLsvsRR CTRLsvsPP MSvsCTRLS 
ANRIL 9.07E-03 1.79E-03 NS NA 
BACE1-AS 0.0006373 0.0001275 0.0004598 NA 
GOMAFU 0.0001312 0.0001401 0.0001383 0.8937 
H19 NS NS NS NA 
HULC 0.0003072 0.0008527 0.0002085 NA 
MALAT1 0.01324 NS NS NA 
MEG9 0.04426 NS NS NA 
NRON 0.02134 0.05792 NS 0.01409 
NESPAS NS NS NS NA 
SOX2-OT 0.000398 0.000725 NS NA 
TUG1 2.61E-02 1.35E-02 NS 2.75E-04 
XIST 0.0000512 0.000169 NS NA 
Table 28. Exact p-values of validation and replication analysis by Wilcoxon-Mann 
Whitney test. NS=not significant; NA=not available 
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Exosomal RNA analysis by Bioanalyzer (Agilent) 
 
Sample 
[RNA] 
(ng/μL) 
1 12.38 
2 19.70 
3 12.99 
4 21.34 
5 12.18 
6 14.67 
7 15.62 
8 19.79 
9 12.54 
10 15.52 
11 18.55 
12 12.83 
13 13.53 
14 10.65 
15 13.50 
16 8.80 
17 13.23 
18 10.25 
19 13.63 
20 12.94 
21 13.00 
22 12.40 
23 12.05 
24 5.90 
mean 13.67 
SD 3.50 
Table 29. Exosomal RNA concentration for each sample 
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Figure 47 Bioanalyser electropherograms of total RNA isolated from L1CAM-exosomes. 
The highest peak is the marker peak, while the lowest are the sncRNA and lncRNA peaks.  
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Figure 48 Bioanalyzer analysis of L1CAM-exosomal RNA. A) and C) Ladder 
electropherogram. We can see the 6 peaks referred to the known-length RNA fragments.  B) 
and D) Gel run of the 24 samples.  
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